The circadian architecture of tumor immunity: mechanistic insights and treatment strategies Authors: Hao Wang, Bin Guo, Danfeng Li, Yuxi Liu, Kun Cheng, Wanguang Zhang, Huifang Liang Published: 2026 ABSTRACT AbstractBackgroundThe circadian clock orchestrates many key physiological processes related to anti-tumor immunity, including the cell cycle, energy metabolism, immune infiltration, and cytokine secretion. Increasing evidence suggests that circadian clock disruption is involved in tumorigenesis and tumor progression. Both clinical and basic research indicate that the circadian clock is a central regulator of tumor immunity and an important target for intervention. However, the role of the circadian clock in remodeling tumor immunity, as well as existing and potential intervention strategies, remains largely uncharacterized.MainTo investigate the role of the circadian clock in tumor immunity, we integrated a tumor-related circadian regulatory framework encompassing the central pacemaker, peripheral cell-autonomous clocks, and environmental and behavioral factors such as sleep and feeding. Evidence from epidemiological, clinical, and translational studies reveals that circadian disruption impairs immune surveillance and promotes tumor initiation and progression, contributing to increased cancer risk and poorer outcomes. We further examine the mechanisms by which circadian dysregulation reshapes the tumor immune microenvironment and alters both innate and adaptive antitumor immunity. Finally, we discuss emerging therapeutic approaches that leverage circadian biology to enhance antitumor immune responses, including circadian clock-targeting interventions and chronotherapy, highlighting their potential to improve cancer treatment outcomes.ConclusionEvidence reviewed here indicates that circadian dysregulation promotes tumor progression through cell-intrinsic clock reprogramming and remodeling of the tumor immune microenvironment. By regulating immune surveillance, metabolic homeostasis, and the function of both immune effector and immunoregulatory cells, the circadian clock plays a central role in antitumor immunity. These findings support the integration of chronotherapy and circadian clock-targeting strategies with immunotherapy to improve the precision and efficacy of cancer treatment.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40364-026-00972-6.Keywords: Circadian clock, Tumor immunity, Tumor immune microenvironment, Immunotherapy Introduction The circadian clock is an endogenous timing system that has evolved to synchronize organisms with the daily light-dark cycle. These rhythms orchestrate various physiological processes, including metabolism, hormone secretion, the cell cycle, and immune responses, to maintain homeostasis, thereby affecting tumor occurrence and progression, and playing a key role in reshaping the tumor immune microenvironment (TIME) [1–5]. Molecularly, the circadian clock is driven by cell-autonomous oscillators and coordinated by central pacemakers, primarily the suprachiasmatic nucleus (SCN), in concert with environmental and behavioral cues such as light exposure, sleep patterns, and feeding cycles [2, 6, 7]. Accumulating evidence indicates a strong connection between circadian disruption and tumorigenesis. Epidemiological, preclinical, and clinical studies consistently demonstrate the carcinogenic and tumor-promoting effects of circadian misalignment [8–10]. Furthermore, recent studies have revealed extensive and complex bidirectional interactions between the circadian system and tumor immunity. Circadian clocks regulate the development, trafficking, and functional activity of immune effector cells—including T cells, natural killer cells (NK cells), dendritic cells, and macrophages—thereby shaping immune surveillance and antitumor responses. Conversely, tumor cells and the inflammatory or metabolic components of the TIME can feed back to disrupt circadian rhythms, exacerbating immune dysfunction and promoting immune evasion [11, 12]. These findings highlight the profound time-dependent nature of tumor immune dynamics and have propelled cancer chrono-immunology to the forefront of oncology research. Despite these advances, a systematic understanding of how circadian clocks regulate tumorigenesis and tumor immunity—and how such insights can be translated into clinical practice—remains limited. In this review, we comprehensively characterize the circadian clock and its tumor-related regulatory network, and further discuss the role of circadian clock disruption in tumor initiation and progression, as well as the impact of circadian regulation on the TIME and tumor immune processes. Thus, we explored emerging and potential strategies for utilizing and targeting the circadian clock to improve tumor response to immunotherapy and other therapies, develop new treatment strategies, and promote clinical translation. Circadian clock regulatory network in immune surveillance Immune surveillance rhythms are orchestrated by a hierarchical regulatory network that integrates neuroendocrine signals driven by the central circadian pacemaker with cell-autonomous molecular circadian clocks. This network is further modulated by environmental and behavioral cues, including light–dark, feeding–fasting, and sleep–wake cycles. Together, these signals generate robust circadian fluctuations in metabolism and immune dynamics (Fig. 1). The functional state and coordination of these regulatory components critically influence the behavior and activity of immune cells. In essence, immune rhythms are governed by three interconnected mechanisms: (1) peripheral cell-autonomous circadian clocks; (2) central rhythmic signals generated by the SCN circadian pacemaker through neuroendocrine pathways; and (3) environmental and behavioral rhythms, including light–dark cycles, feeding–fasting cycles, and sleep–wake cycles. These mechanisms interact synergistically, reciprocally regulate one another, and can serve compensatory functions [13] (Fig. 1). Regulatory network of the circadian clock. The circadian clock in tumor immunity is orchestrated by several interconnected systems: (1) The suprachiasmatic nucleus (SCN) in the hypothalamus functions as the central pacemaker, synchronizing peripheral clocks via neuroendocrine signals such as glucocorticoids; (2) Behavioral rhythms, including feeding and sleep, influence peripheral clocks through metabolic cues such as cAMP response element-binding protein (CREB) and heat shock factor 1 (HSF1). Insulin/insulin-like growth factor 1 (IGF-1) signaling activates the IR/IGF-1R–PI3K–PIP3–mTORC1 axis to enhance period circadian regulator 2 (PER2) expression and facilitate circadian entrainment. In addition, insulin suppresses PER-targeting miRNAs, enhancing PER protein translation and contributing to peripheral clock phase resetting. Under nutrient deprivation, reduced insulin promotes free fatty acids (FFA) release and activates peroxisome proliferator-activated receptor α (PPARα), which induces Rev-Erbα via direct repeat 2 (DR2) response elements, thereby modulating core clock function. Insulin also regulates REV-ERBα stability through the AKT–GSK3β axis. Furthermore, oxyntomodulin (OXM) signaling via the GCGR–PKA–CREB pathway promotes period circadian regulator 1 (PER1)/PER2 transcription. Together, these pathways integrate nutritional status into molecular clock regulation, linking metabolism to tumor immune rhythms Peripheral cell-autonomous core circadian clock The core transcription–translation feedback loop (TTFL) of the cell-autonomous circadian oscillator is centered on the CLOCK and BMAL1 proteins, which form a heterodimeric basic helix–loop–helix–PER–ARNT–SIM (PAS) positive transcription factor complex, CLOCK: BMAL1 [14, 15]. This complex translocates into the nucleus, where it binds to E-box regulatory elements and recruits RNA polymerase II (RNAP II) to initiate transcription of hundreds of rhythmically expressed genes. These include the transcription factor subunits period circadian regulator 1 (PER1)/PER2/period circadian regulator 3 (PER3), cryptochrome1 (CRY1)/cryptochrome2 (CRY2), and nuclear receptors of the circadian clock, such as the retinoic acid–related orphan receptors retinoic acid–related orphan receptor alpha (RORα)/retinoic acid–related orphan receptor beta (RORβ)/retinoic acid–related orphan receptor gamma (RORγ) and nuclear receptor subfamily 1 group D members (REV-ERBα/β, NR1D1/2). In the cytoplasm, PER and CRY proteins form heterodimers and translocate back into the nucleus, where they interact with CLOCK: BMAL1. While recruiting RNAP II, they repress transcription initiation, thereby inhibiting CLOCK: BMAL1-driven transcription of PER and CRY genes. This constitutes the core negative transcriptional feedback loop of the circadian oscillator [16]. PER and CRY proteins undergo continuous ubiquitin-dependent proteasomal degradation [17–20]. This negative feedback, together with protein degradation, reduces PER and CRY synthesis, causing their nuclear levels to gradually decline. Therefore, CLOCK: BMAL1-mediated activation of PER1/PER2/PER3 and CRY1/CRY2 transcription is released, leading to increased mRNA and protein expression. PER and CRY proteins subsequently accumulate in the nucleus, re-establishing inhibition of CLOCK: BMAL1 and thereby reducing their own transcription. This oscillatory cycle repeats approximately every 24 h, generating a stable, foundational circadian rhythm. The retinoic acid–related orphan receptors (RORs) family functions as positive transcriptional regulators by binding to RORE elements upstream of the BMAL1 gene, which is critical for its normal expression [21], whereas REV-ERBα acts as a transcriptional repressor by competing with RORα [22]. Both RORα/β/γ and NR1D1/2 genes are located downstream of E-box elements and are regulated by CLOCK: BMAL1. Consequently, two interlocking TTFLs—CLOCK: BMAL1–REV-ERBα/RORα and CLOCK: BMAL1–PER: CRY—constitute the core molecular mechanism of the cell-autonomous circadian oscillator. The CLOCK: BMAL1–PER: CRY loop serves as the fundamental timekeeping oscillator, analogous to the cellular circadian “clockwork,” while CLOCK: BMAL1–REV-ERBα/RORα fine-tunes and synchronizes responses to internal and external environmental and metabolic cues, playing a crucial role in maintaining oscillator stability. The rhythmic regulation and homeostasis of metabolism and immune responses critically depend on the proper functioning of the cell-autonomous core circadian clock. Dysfunction of this core clock directly results in marked metabolic dysregulation and impaired immune surveillance [23, 24]. Central circadian pacemaker in the SCN The central circadian pacemaker, located in the SCN of the hypothalamus, represents the body’s most robust and stable circadian oscillator. It synchronizes cell-autonomous clocks with environmental geophysical cycles, primarily through photic input. By receiving light signals, the SCN entrains cellular metabolic rhythms to the external light–dark cycle and functions as the central hub for integrating photic information and distributing it throughout the body via neuroendocrine pathways. Hence, peripheral circadian rhythms are coordinated and aligned with environmental cues [25]. Among these systemic outputs, glucocorticoid rhythms—regulated by the SCN—serve as a key hormonal signal that entrains peripheral clocks and modulates immune surveillance [26]. Beyond neuroendocrine outputs, additional SCN-regulated cues, such as body temperature oscillations, also contribute to the entrainment of immune cell functional states, providing alternative synchronizing mechanisms for SCN-mediated circadian regulation [25, 27]. The SCN itself comprises a tightly coupled network of neurons that express core molecular clock components similar to those in peripheral tissues [27, 28]. However, unlike peripheral clocks, SCN neurons are highly resistant to fluctuations in internal physiological signals such as hormones and temperature, thereby maintaining circadian precision despite internal noise [29]. In contrast, SCN neurons are exquisitely sensitive to photic input, allowing accurate alignment with the environmental light–dark cycle [30]. Under physiological conditions, this neuronal network generates a stable, light-entrained ~ 24-hour rhythm that orchestrates rhythmic outputs across the body. The SCN achieves this coordination by driving systemic neuroendocrine oscillations, which in turn entrain cellular clocks in peripheral tissues [31, 32]. Feeding-fasting cycles regulate the circadian clock Feeding rhythms are shaped by both intrinsic appetite regulation under the control of the SCN and by extrinsic environmental factors that govern food accessibility. These rhythms significantly impact multiple biological processes associated with tumor immune regulation. The metabolic status and rhythmic fluctuations of immune surveillance are closely coupled to feeding-fasting rhythms as nutrient intake directly influences the availability of metabolic substrates and systemically modulates circadian clocks, beginning at the transcriptional level [33]. Experimental evidence indicates that feeding–fasting cycles act as potent zeitgebers, driving rhythmic gene expression through nutrient-sensitive transcription factors, including cAMP response element-binding protein (CREB) and heat shock factor 1 (HSF1). Importantly, oscillatory transcription of metabolism- and clock-associated genes can persist even under conditions of SCN ablation or disruption of cell-autonomous clocks, underscoring the dominant entrainment capacity of feeding cues. These findings highlight nutrient availability as a critical circadian regulator with the potential to influence systemic metabolic homeostasis and immune function [33, 34]. Feeding-driven metabolic rhythms are orchestrated through intricate endocrine and nutrient-sensing pathways involving hormones and metabolites such as glucose, glucagon, and oxyntomodulin [35–37]. These signals activate downstream cascades that regulate gene expression and cellular functions in a time-of-day–dependent manner. The major validated mechanisms by which feeding entrains immune and metabolic rhythmicity are integrated below (Fig. 1): Insulin/IGF-1 regulates PER2 through the PI3K–PIP3–mTORC1 pathway Insulin and insulin-like growth factor 1 (IGF-1) engage their respective receptors, the insulin receptor (IR) and IGF-1 receptor (IGF-1R), to activate phosphoinositide 3-kinase (PI3K), which catalyzes the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [38]. This signaling cascade stimulates the mammalian target of rapamycin complex 1 (mTORC1) [39], thereby enhancing PER2 protein synthesis through increased translational efficiency. Through this mechanism, nutrient availability is coupled to the regulation of the cell-autonomous circadian oscillator, synchronizing cellular metabolism and immune functions with feeding–fasting cycles. Insulin/IGF-1-mediated suppression of PER-targeting miRNAs Certain microRNAs (miRNAs) regulate the translation efficiency and stability of PER1/2/3 and CRY1/2 mRNAs by targeting these transcripts, introducing necessary time delays between mRNA synthesis and protein expression. Insulin and IGF-1 selectively suppress the expression of miRNAs that target PER1/2/3 transcripts [40, 41], thereby enhancing PER1/2/3 mRNA translation efficiency and accelerating the post-transcriptional accumulation of PER1 and PER2 proteins. This facilitates rapid PER protein buildup in peripheral tissues, enabling nutrient-induced phase resetting of peripheral clocks and aligning circadian rhythms with metabolic status [42]. Insulin–FFA–PPARα–REV-ERBα pathway During fasting, decreased insulin and glucose levels promote lipolysis, leading to elevated circulating free fatty acids (FFAs) [43]. These FFAs activate peroxisome proliferator-activated receptor alpha (PPARα) [44], which binds to direct repeat 2 (DR2) motifs within the NR1D1 promoter, driving its transcription independently of BMAL1 [45]. This signaling axis establishes a direct link between lipid metabolism and circadian regulation, enabling nutrient-responsive modulation of NR1D1 expression and allowing peripheral clocks to adapt dynamically to changes in energy availability. Insulin–IR–protein kinase B (AKT)–glycogen synthase kinase-3 (GSK3) β–REV-ERBα pathway This pathway exhibits bidirectional control of REV-ERBα stability. Insulin stimulation activates AKT via the IR–PI3K axis, leading to phosphorylation of glycogen synthase kinase-3β (GSK3β) and suppression of its kinase activity. As GSK3β mediates phosphorylation-dependent proteasomal degradation of REV-ERBα, its inhibition reduces REV-ERBα phosphorylation and consequently stabilizes the protein [46]. Therefore, insulin signaling dynamically regulates nuclear REV-ERBα levels, shaping its circadian expression pattern [43]. OXM–GCGR–PKA–CREB–PER1/PER2 pathway Oxyntomodulin (OXM), a gut-derived peptide hormone, activates the glucagon receptor (GCGR), initiating a signaling cascade that involves activation of protein kinase A (PKA) and subsequent phosphorylation of CREB [47]. Similar to other gluconeogenic pathway proteins, cAMP-response elements (CRE) motifs located upstream of PER1 and PER2 genes mediate CREB-dependent transcriptional activation. Phosphorylated CREB has been shown to enhance PER1 and PER2 transcription, directly linking gut hormone signaling to circadian gene regulation [48]. Circadian rhythms of the gut microbiota regulate systemic immune responses In addition to endocrine and nutrient-sensing pathways, emerging evidence indicates that feeding–fasting rhythms can drive systemic immune rhythmicity by regulating of gut microbiota oscillations and signaling within the gut-associated lymphoid tissue (GALT). Under the combined influence of feeding rhythms and their associated endocrine, bile acid, and intestinal motility rhythms, the gut microbiota exhibits pronounced circadian oscillations in microbial composition, metabolic activity, adhesive behavior, and migratory capacity [49]. For example, members of the Firmicutes phylum typically expand during feeding phases, whereas Bacteroidetes display enhanced polysaccharide degradation activity during fasting periods [50]. Consequently, microbiota-derived immunoregulatory metabolites—including short-chain fatty acids (SCFAs), secondary bile acids, and indole derivatives—are not produced continuously at stable levels but instead exhibit marked diurnal oscillations [51]. Based on the highly dynamic interaction between microbial circadian rhythms and GALT, the gut microbiota regulates host immune surveillance in a temporally structured manner. Among microbial metabolites, SCFAs, particularly acetate, propionate, and butyrate, are considered key mediators linking the “microbial clock” to systemic immune rhythmicity [52, 53]. SCFAs are generated through microbial fermentation of dietary fiber, resistant starch, and mucin-derived glycans, leading to postprandial increases and fasting-associated decreases in SCFA levels. These oscillations are synchronized with host circadian clock gene expression, thereby establishing a form of “metabolic time coding” that conveys temporal information regarding nutrient status and metabolic activity to the immune system [52]. GALT serves as a critical interface through which these rhythmic microbial signals influence systemic immune surveillance. As one of the body’s largest immune organs, GALT comprises Peyer’s patches, mesenteric lymph nodes, lamina propria immune cells, IgA-producing plasma, M, and innate lymphoid cells (ILCs), collectively maintaining intestinal immune homeostasis [54]. Current evidence suggests that GALT activation is dynamically driven by rhythmic production of microbial metabolites [55]. SCFAs function not only as metabolic substrates but also as potent immunoregulatory signaling molecules. SCFAs bind to G protein-coupled receptors expressed on dendritic cells, macrophages, neutrophils, regulatory T cells (Tregs), and intestinal epithelial cells, including free fatty acid receptor 3 (FFAR3), free fatty acid receptor 2 (FFAR2), and hydroxycarboxylic acid receptor 2 (HCAR2). Through activation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) signaling pathways, SCFAs promote the expression of cytokines such as IL-10, IL-18 and IL-22, which modulate inflammasome activity and enhance epithelial barrier repair [55, 56]. Through these mechanisms, rhythmic SCFA production translates “microbial metabolic time” into “immune activation time,” thereby coordinating systemic immune responses with feeding rhythms. In addition, butyrate exerts important epigenetic regulatory effects through inhibition of histone deacetylase 3 (HDAC3), leading to increased histone acetylation, enhanced Foxp3 expression, and promotion of Treg differentiation [52]. This process also displays clear temporal dependence: elevated SCFA levels during feeding phases favor immune tolerance and anti-inflammatory programs, whereas fasting phases may increase tissue sensitivity to inflammatory stimuli. Thus, microbial metabolic rhythms may establish temporal windows of immune tolerance and inflammatory responsiveness through dynamic regulation of Treg populations. Furthermore, SCFAs can directly regulate core circadian clock genes in intestinal epithelial cells, including BMAL1, CLOCK, PER, and NR1D1 [57]. For example, butyrate has been shown to influence CLOCK/BMAL1 activity through the AMP-activated protein kinase (AMPK)–Sirtuin 1 (SIRT1) pathway, thereby reshaping intestinal epithelial circadian rhythms [57]. Importantly, immune rhythmicity initiated through GALT is not confined to the intestine but can extend to systemic immune regulation. SCFA-induced Tregs can migrate to peripheral tissues including the lung, liver, adipose tissue, and central nervous system, thereby modulating systemic inflammatory tone and immune tolerance [58, 59]. In addition, circulating SCFAs—particularly propionate—can directly act on bone marrow hematopoietic progenitor cells, influencing myeloid differentiation, monocyte maturation, and neutrophil rhythmicity, suggesting that gut-derived metabolites can remotely regulate innate immune function [60, 61]. Meanwhile, SCFAs entering the liver through the portal circulation can modulate Kupffer cell activity, toll-like receptor (TLR) signaling thresholds, and acute-phase inflammatory responses, thereby further influencing systemic inflammatory homeostasis [62, 63]. Recent evidence further indicates that microbiota-derived butyrate can directly influence antitumor adaptive immunity. Butyrate has been shown to promote a FOXO1-dependent stem-like transcriptional program in CD8⁺ T cells, thereby preserving their proliferative capacity, persistence, and long-term effector potential during chronic antigen exposure. Through the maintenance of stem-like CD8⁺ T cell states and prevention of terminal exhaustion, microbiota-derived metabolites may contribute to sustained antitumor immune surveillance and improved responsiveness to immunotherapy [64]. Collectively, rhythmic microbial metabolites within the gut constitute an important component of feeding-dependent circadian regulation. Through GALT-mediated immune signaling, they tightly connect intestinal clocks, metabolic homeostasis, and systemic immune surveillance. Conversely, disruption of feeding rhythms, circadian misalignment, or impaired microbial oscillations—such as those induced by shift work, high-fat low-fiber diets, chronic sleep disturbance, or antibiotic exposure—can lead to flattening of SCFA rhythms and disruption of GALT rhythmicity, thereby promoting chronic inflammation, metabolic dysfunction, and tumor-associated immune abnormalities. Therefore, the microbiota–GALT rhythmic axis may represent a critical mechanistic bridge linking feeding rhythms to temporal regulation of the TIME. Role of intestinal circadian clocks in tumor immune rhythms It is increasingly recognized that the intestinal circadian clock system serves as a central coordinator integrating feeding rhythms, endocrine oscillations, metabolic status, and systemic immune rhythmicity. The intestine not only recognizes nutritional status through glucose, lipid, and hormonal signals, but also converts feeding–fasting rhythms into metabolic and immune timing cues for peripheral tissues through a local rhythmic network composed of intestinal epithelial and enteroendocrine cells, and the gut microbiota. Therefore, the intestine is now considered an important integrative organ linking behavioral, metabolic, and immune rhythms [65]. Rhythmic expression of core clock components in intestinal epithelial cells, including CLOCK, BMAL1, PER, and REV-ERBα, drives circadian oscillations in multiple metabolic pathways through transcriptional reprogramming. These include key metabolic genes involved in lipid (e.g., FASN and ACACA), glucose (e.g., GCK and PKLR), amino acid (e.g., DHTKD1 and ALDH1B1), and nucleotide (e.g., UCK1 and PNP2) metabolisms. Such metabolic oscillations further influence cellular energy supply, redox homeostasis, and immune cell function, thereby contributing to the establishment of systemic immune surveillance rhythmicity [66, 67]. Importantly, the intestinal circadian clock does not operate in isolation but is highly coupled to the nutrient-sensing pathways and microbiota rhythmicity described above. Feeding rhythms can directly reset the intestinal clock through fluctuations in insulin, IGF-1, free fatty acids, and glucose levels. Conversely, microbiota-derived metabolites, including SCFAs, bile acids, and indole derivatives, can regulate oscillations of intestinal epithelial clock genes through mechanisms involving the AMPK–SIRT1 axis, HDAC inhibition, and GPCR-mediated signaling. Thus, the intestinal clock appears to reside at the intersection of the “nutrition–microbiota–immunity” rhythmic network, integrating endocrine, metabolic, and microbial-derived signals to coordinate temporally structured metabolic activities in both local and peripheral tissues. Although the precise mechanisms by which the intestinal clock directly regulates tumor immune surveillance rhythmicity remain incompletely understood, accumulating evidence suggests that peripheral insulin sensitivity and immunometabolic status are closely associated with intestinal circadian integrity. For example, the gut-derived hormone OXM can regulate peripheral clock gene expression through the GCGR–PKA–CREB–PER1/PER2 signaling axis, suggesting that rhythmic intestinal hormone secretion may serve as an important intermediary linking feeding behavior with peripheral circadian regulation. In addition, intestinal circadian disruption may further impair systemic immune homeostasis and promote chronic inflammation and immune dysregulation within the TIME by disrupting microbial oscillations, reducing rhythmic SCFA production, and perturbing GALT immune rhythmicity. In summary, the intestinal circadian clock may function not only as a critical regulator of metabolic homeostasis but also as a key node coordinating feeding rhythms, microbial oscillations, and systemic antitumor immune rhythmicity. Through integration of nutritional signals, microbiota-derived metabolites, and endocrine rhythms, the intestinal clock helps shape the temporally organized immunometabolic landscape of peripheral tissues, thereby influencing the dynamic immune status and therapeutic sensitivity of the TIME [68, 69]. Collectively, these mechanisms illustrate how feeding rhythms, acting as key drivers of the cellular circadian clock, shape tumor cell behavior by regulating metabolism, proliferation, and apoptosis through insulin–PI3K–related signaling pathways. Robust experimental evidence from both cellular and animal models substantiates this regulatory axis [70, 71]. Moreover, recent studies have uncovered a bidirectional relationship between peripheral metabolic rhythms and feeding behavior, mediated by vagal afferent signaling from peripheral tissues to the brain [72]. This finding raises important questions about how metabolic activities within the TIME may, in turn, modulate both central and peripheral circadian rhythms. Preclinical studies have shown that feeding rhythm interventions, such as time-restricted feeding (TRF), can markedly suppress tumor growth. Mechanistically, TRF enhances anti-tumor activity by activating autophagy pathways through modulation of circadian gene expression. Integrated metabolomic and transcriptomic analyses further demonstrate that TRF reprograms circadian metabolic rhythms within tumor tissues—particularly those governing energy and lipid metabolism—while simultaneously promoting immune activation and apoptosis signaling pathways [73]. Interaction between the cellular circadian clock and macroscopic rhythm The circadian regulation of fundamental cellular processes—including transcription, metabolism, and biosynthesis—is governed by a complex interplay among the central pacemaker in the SCN, cell-autonomous circadian oscillators, and external rhythmic cues such as the sleep–wake and feeding–fasting cycles. Synchronizing these processes with systemic physiological states requires precise intracellular integration of diverse rhythmic signals. REV-ERBα, a nuclear receptor and core repressor of the circadian machinery, plays a central role in this integrative process. Its expression and activity are tightly modulated by systemic cues such as glucocorticoids and body temperature, while its ligand-dependent activation by heme links REV-ERBα to cellular redox status and metabolic fluctuations [74–77]. Through these mechanisms, REV-ERBα acts as a molecular hub, translating endocrine, metabolic, and environmental inputs into circadian regulation at the cellular level, thereby ensuring that metabolic and immune rhythms remain aligned with behavioral and environmental cycles such as feeding and sleep. Importantly, REV-ERBα is also a key regulator of metabolism and immune function. It represses lipogenic gene expression through rhythmic recruitment of HDAC3, thereby maintaining lipid metabolic homeostasis [78–83]. In vivo studies confirm that glucose and lipid metabolism are closely linked to REV-ERBα levels and activity, with metabolic homeostasis strongly dependent on REV-ERBα–mediated transcriptional control [78, 83–85]. In the context of immune surveillance, REV-ERBα modulates immune effector function through suppression of enhancer RNA transcription and downregulation of matrix metalloproteinase 9 (MMP9) [86]. In our previous study, we demonstrated that elevated MMP9 impairs CD8⁺ T cell infiltration and cytotoxicity, thereby fostering an immunosuppressive TIME and contributing to resistance to anti–programmed cell death protein 1 (PD-1) therapy. Mechanistically, we found that MMP9 promotes the shedding of phosphatase slingshot homolog 1 (SSH1) from the CD8⁺ T cell surface, disrupting C-X-C chemokine receptor type 3 (CXCR3)-mediated G protein-coupled receptor (GPCR) signaling and impairing T cell trafficking and activation [87]. These findings suggest that repression of MMP9 may represent an important mechanism through which REV-ERBα enhances antitumour immunity. Nevertheless, these findings were primarily derived from analyses focused on the mechanistic consequences of MMP9 dysregulation rather than its circadian dynamics. Whether REV-ERBα dependent oscillations in MMP9 expression translate into time-of-day–dependent changes in CD8⁺ T cell trafficking and antitumour immunity remains to be determined. Together, these findings position REV-ERBα as a central node coupling immune surveillance rhythmicity to systemic behavioral and metabolic rhythms. As a transcriptional target of the CLOCK: BMAL1–PER: CRY feedback loop, REV-ERBα mediates circadian regulation of lipid and energy metabolism, effectively relaying intracellular timekeeping signals to downstream metabolic pathways. Simultaneously, as a direct transcriptional repressor of BMAL1, it remains highly responsive to systemic cues such as hormonal changes, temperature fluctuations, and redox state. This bidirectional regulatory role enables systemic physiological rhythms to feed back into and modulate the core circadian oscillator via REV-ERBα. Thus, REV-ERBα emerges as a key molecular hub that aligns intrinsic cellular circadian clocks with whole-organism behavioral and metabolic states. Notably, disruption of REV-ERBα function does not abolish core circadian oscillations but instead decouples intracellular metabolic rhythms from systemic cycles such as feeding and rest. Under conditions of stable systemic rhythmicity, this decoupling may be subclinical; however, when behavioral rhythms are disrupted—e.g., by feeding schedule alterations—misalignment between intracellular metabolic activity and nutrient availability becomes pathologically evident. This phenomenon was elegantly demonstrated by Louise Hunter et al., who found that NR1D1 knockdown had minimal impact on circadian gene expression under stable feeding conditions but led to pronounced metabolic dysfunction, including lipid accumulation and aberrant transcriptional profiles, when feeding rhythms were disturbed [88]. These insights reconceptualize REV-ERBα not as a sole driver of circadian metabolic rhythms [78, 79, 82, 83, 89], but as a dynamic coupling agent that buffers the circadian clock against perturbations in systemic metabolic cues, thereby maintaining coherence between cellular timekeeping and organismal behavior [66]. In summary, REV-ERBα not only tunes immune surveillance rhythmicity to behavioral cycles such as feeding and sleep, but also mediates reciprocal feedback between the cell-autonomous circadian oscillator and cellular metabolic states. This positions REV-ERBα as a crucial integrator at the interface of immunity, metabolism, and systemic circadian regulation. Disruption of circadian clock promotes tumor occurrence and progression Epidemiology A growing body of epidemiological evidence has demonstrated that circadian disruption, such as that caused by shift work, sleep deprivation, or irregular feeding schedules, is closely linked to an increased risk of various cancers. While the precise mechanisms by which circadian dysregulation contributes to tumor initiation and progression remain to be fully elucidated, epidemiological evidence strongly implicates the circadian clock in cancer development. The incidence of malignant tumors has increased in recent decades [90–93]. This phenomenon can be attributed to several factors, including the increase in average life span, the popularity of examinations, environmental pollution, and mental stress. The general disorder of diet and sleep rhythm in modern social life has also been confirmed to be an important factor affecting tumor occurrence and prognosis [94, 95]. Among specific occupational groups such as doctors, nurses, police officers, and workers who experience irregular eating and sleeping patterns due to shift work, as well as among young people with unhealthy habits such as staying up late and consuming late-night meals, the importance of circadian rhythm in tumor epidemiology and prognosis is receiving increasing attention. Clinical and preclinical studies have demonstrated that disruptions in the daily routine including sleep and diet promote the occurrence of various tumors, including lung, liver, breast, prostate, blood tumor, colorectal, ovarian and endometrial cancers [94, 96–103] (Fig. 2). Reflecting this evidence, the International Agency for Research on Cancer (IARC) has classified “shift work that involves circadian disruption” as a Group 2 A probable human carcinogen [95]. Prospective cohort studies further support these findings; for instance, data from the Nurses’ Health Study indicate that prolonged night shift work is significantly linked to a higher risk of colorectal cancer [104]. Furthermore, studies have shown that circadian rhythm interventions, such as reinforcing time-restricted feeding (TRF) windows and extending nighttime fasting substantially reduce the risk of breast and prostate cancers [105, 106]. Circadian disruption promotes tumorigenesis. Disruption of circadian rhythms caused by shift work, irregular feeding schedules, and sleep deprivation alters endocrine, metabolic, autonomic nervous system, and immune surveillance rhythms. These disturbances interfere with key cellular processes, including cell cycle regulation, apoptosis, inflammatory responses, and DNA repair, thereby facilitating tumor initiation and progression. Circadian disruption perturbs endocrine, metabolic, and immune homeostasis, thereby increasing cancer risk and promoting tumor progression. Concurrently, impaired immune surveillance—characterized by reduced NK cell function, altered T-cell populations, and increased immunosuppressive myeloid cells—further accelerates tumor growth and metastasis. Collectively, circadian disruption increases the risk and worsens the prognosis of multiple cancers, including lung, liver, breast, prostate, colorectal, hematological, ovarian, and endometrial cancers Findings from clinical research, epidemiological studies, and evidence-based medicine have confirmed the important role of circadian rhythm in tumorigenesis, particularly in specific populations. These results highlight the important role of the circadian clock in the regulation of tumor occurrence, progression, and tumor immunity. Circadian misalignment induces endocrine, metabolic, and immune disturbances that collectively increase cancer susceptibility and promote disease progression [107] (Fig. 2). External circadian disruption regulates tumor occurrence and progression Circadian clock disturbance—particularly chronic sleep deprivation—significantly impairs immune surveillance. Sleep deprivation reduces the number and cytotoxic function of NK cells, thereby weakening their ability to recognize and eliminate malignant cells [108, 109], and depletes mature, tumor-reactive T cell populations while promoting infiltration of immunosuppressive CD11b⁺ cells, including myeloid-derived suppressor cells (MDSCs) and M2-polarized macrophages. Collectively, these immune alterations foster immune evasion and accelerate tumorigenesis [110]. Circadian misalignment further disrupts the rhythmic trafficking of immune cells and the oscillatory secretion of cytokines, which together compromise the efficacy of immune responses and reduce responsiveness to immunotherapeutic interventions [111]. In vivo studies have demonstrated that both sleep deprivation and circadian rhythm disturbance promote tumor growth and metastasis, while concurrently diminishing the effectiveness of immune checkpoint blockade therapies [112, 113]. Studies have also found that restoring the expression of core circadian genes CLOCK and BMAL1 significantly reduces proliferation rates and prolongs the cell cycle, particularly by inducing arrest in the G1 phase. In vivo experiments further demonstrate that tumors derived from cancer cells with enhanced circadian function are markedly smaller in mice, underscoring a direct role of the circadian clock in restraining cell proliferation and maintaining tumor homeostasis. Mechanistically, strengthening circadian function modulates a range of downstream pathways involved in cell cycle progression, metabolism, and DNA repair [107]. Growing clinical evidence suggests that restoring circadian alignment through behavioral interventions may improve outcomes in patients with cancer. Lifestyle factors that reinforce circadian rhythmicity, including regular sleep-wake schedules, improved sleep quality, appropriately timed food intake, and maintenance of daily activity rhythms, have been associated with better physical function, reduced cancer-related fatigue, improved metabolic health, and potentially enhanced survival [114–116]. These findings support the concept that circadian health represents a modifiable factor that may complement conventional cancer therapies and contribute to improved patient prognosis. The role of circadian clock reprogramming in tumorigenesis and progression Circadian clock reprogramming in cancer cells During malignant transformation, the circadian clock in cancer cells is often disrupted or reprogrammed to accommodate heightened proliferative and metabolic demands. Under physiological conditions, the TTFL driven by CLOCK and BMAL1 maintains robust 24-h rhythms, regulating key cellular processes such as cell cycle progression, DNA repair, and energy metabolism. Cancer cells frequently reprogram the circadian clock through reciprocal interactions between core clock components and oncogenic signaling pathways. Upregulation of MYC and HIF-1α suppresses the expression of core clock genes and disrupts circadian rhythmicity. In particular, MYC directly binds to the BMAL1 promoter and represses its transcription, thereby uncoupling cell proliferation from normal circadian control [117]. Concurrently, circadian clock disruption is associated with dysregulation of key cell-cycle regulators and tumor suppressor pathways, including increased MYC and CCND1 activity and attenuation of TP53 signaling [118]. These alterations impair apoptotic responses, promote uncontrolled proliferation, and facilitate tumor progression [119]. These disruptions are especially pronounced in highly aggressive tumors and are tightly linked to cell cycle dysregulation [120–122]. Collectively, the reciprocal crosstalk between clock gene dysfunction and oncogenic pathways establishes a self-reinforcing state of circadian clock reprogramming that supports malignant growth and survival. Although cancer cells retain rhythmic activity in processes such as transcription, translation, metabolism, and cell cycle regulation, the identity of rhythmically expressed genes diverges significantly from that of normal cells. Specifically, the overlap of rhythmic genes between tumor and normal cells accounts for less than 20% of total rhythmic transcripts in either group. Enrichment analyses indicate that this shared subset is largely confined to core circadian regulators. Moreover, even among overlapping genes, the phase of peak expression is markedly shifted between tumor and normal cells [123]. These findings suggest that cancer cells do not completely lose circadian control; rather, they reprogram circadian rhythms to support malignant phenotypes. Certain cancer cells retain—or even enhance—the function of specific clock components but repurpose the overall regulatory architecture to promote oncogenic processes such as cell cycle progression, DNA replication, and redox homeostasis, at the expense of physiological rhythmicity [121, 124–126]. For example, the oncogene MYC can directly interfere with circadian gene expression, establishing a non-canonical circadian program that facilitates malignant transformation [96, 117, 127–129]. This functional reconfiguration of the circadian clock enables tumor cells to adapt to microenvironmental stress, evade immune surveillance, and acquire resistance to therapy. Clock reprogramming contributes to multiple cancer hallmarks, including sustained proliferative signaling, evasion of growth suppression, resistance to apoptosis, replicative immortality, angiogenesis, invasion and metastasis, metabolic reprogramming, and immune evasion [12, 124, 130–158] (Supplementary Table S1, Fig. 3). Circadian regulation of tumor hallmarks. The circadian clock exerts broad regulatory control over key tumor hallmarks. In cancer stem cells (CSCs), CLOCK/BMAL1 signaling supports stemness by regulating metabolism and transcription factors, whereas PER2 impairs CSC function via cell-cycle arrest. BMAL1/CLOCK promotes tumor invasion by upregulating MMPs and transforming growth factor-β (TGF-β) signaling, facilitating epithelial-mesenchymal transition (EMT) and cancer-associated fibroblast (CAF) activation. PER and CRY participate in DNA damage response pathways, ataxia-telangiectasia mutated proteins (ATM)/Checkpoint kinase 1 (CHK2), and ATM and Rad3-related kinase (ATR)/Checkpoint kinase 2 (CHK1), preserving genomic stability. CLOCK/BMAL1 promote angiogenesis via the hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) axis and TANK-binding kinase 1 (TBK1) signaling; their dysregulation may compromise the efficacy of anti-angiogenic therapies. Circadian reprogramming of glycolysis and mitochondrial metabolism drives lactate accumulation and an immunosuppressive TIME, thereby helping to avoid immune destruction. Collectively, these circadian-controlled processes converge on multiple tumor hallmarks, highlighting the circadian clock as a central orchestrator of cancer initiation and progression Circadian regulation of proliferative signaling and replicative immortality The circadian clock plays a pivotal role in coordinating cell cycle progression by regulating the expression and activity of key cell cycle regulators such as Cyclin D1, Wee1, and c-MYC, thereby ensuring orderly transitions and proper checkpoint function in healthy cells. This temporal gating acts as a critical safeguard against uncontrolled proliferation. However, in cancer cells, circadian gene expression is frequently disrupted or reprogrammed, leading to loss of rhythmic control over the cell cycle [125]. Negative regulators of the circadian clock, such as PER1/2/3 and CRY1/2, are frequently downregulated in tumors, weakening their ability to restrain cell cycle progression [159]. Conversely, overexpression of circadian repressors—including CRY1, CRY2, and PER2—has been shown to inhibit tumor cell proliferation and malignancy by inducing cell cycle arrest and promoting p53-dependent apoptosis [160]. Specifically, CRY1 and CRY2 modulate the MAPK pathway by rhythmically regulating extracellular signal-regulated kinase (ERK) phosphorylation, thereby influencing G1-to-S phase progression [161]. In lung and glioma cells, BMAL1 knockdown enhances PI3K activity and AKT phosphorylation, promoting proliferation and resistance to apoptosis, whereas restoration of BMAL1 expression reverses these effects and reinstates growth inhibition [137] (Fig. 3). In addition to direct regulation of cell cycle genes, circadian dysregulation in tumor cells facilitates malignant growth through destabilization of p53 signaling, increased c-MYC activity, and altered chromatin remodeling, thereby enhancing DNA replication and tumor progression [162–164]. This breakdown of coordination between the circadian clock and cell cycle checkpoints represents a key molecular mechanism in oncogenesis. Importantly, these disruptions may offer a therapeutic opportunity: the temporal desynchronization between tumor and normal cell proliferation could be exploited for chronotherapy, enabling time-dependent administration of anticancer agents that selectively target tumor cells when they are most vulnerable, while minimizing toxicity to normal tissues. Circadian clock regulation of cancer stemness and resistance to cell death BMAL1 and CLOCK, the core components of the circadian transcriptional machinery, can enhance cellular antioxidant defense by upregulating or stabilizing nuclear factor erythroid 2–related factor 2 (NRF2), a master regulator of oxidative stress responses. Through the activation of NRF2-dependent transcriptional programs, BMAL1/CLOCK signaling promotes the expression of key anti-ferroptotic genes, including solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) [165]. The increased expression of these genes elevates intracellular glutathione levels, mitigates lipid peroxidation, and consequently suppresses ferroptotic cell death [166]. This regulatory axis highlights a critical link between circadian rhythm and redox homeostasis, suggesting that the molecular clock confers temporal control over ferroptosis susceptibility in tumor cells. Cancer stem cells (CSCs) represent a subpopulation of tumor cells with self-renewal capacity and tumorigenic potential, driving cancer initiation, metastasis, and thereby resistance. In malignancies such as acute myeloid leukemia (AML) and glioblastoma (GBM), the maintenance of CSC phenotypes is critically dependent on the circadian clock [12, 124, 167]. Beyond orchestrating circadian rhythms, core clock components directly sustain CSC identity by regulating metabolic pathways and the expression of stemness-associated transcription factors, including c-MYC, SRY-box transcription factor 2 (SOX2), and oligodendrocyte transcription factor 2 (OLIG2) [124]. In CSCs, BMAL1 and CLOCK preferentially bind to open chromatin regions, transcriptionally activating genes involved in the tricarboxylic acid (TCA) cycle and enhancing mitochondrial oxidative metabolism to support stemness. Silencing BMAL1 or CLOCK disrupts these processes, leading to cell cycle arrest and apoptosis, thereby impairing CSC self-renewal and proliferative capacity [12]. In contrast, negative regulators such as PER2 and CRY1 are often downregulated in multiple cancer types. In glioma stem-like cells, PER2 expression is significantly reduced compared to that in non-stem-like counterparts. Forced overexpression of PER2 suppresses stemness-associated markers, induces G0/G1 cell cycle arrest, and inhibits malignant behaviors [12, 124]. Furthermore, chronic circadian disruption—such as recurrent jet lag—exacerbates PER2 downregulation while enriching for CSC markers and promoting proliferation [168]. BMAL1 normally exerts an inhibitory effect on PI3K–AKT signaling; therefore, when BMAL1 expression is reduced or its circadian regulation is disrupted in tumor cells, the PI3K–AKT pathway becomes persistently hyperactivated [137, 169]. Our recent work demonstrates that excessive AKT activation not only promotes tumor cell proliferation and metabolic activation but also enhances cellular stress tolerance. In this context, AKT directly phosphorylates phosphoenolpyruvate carboxykinase 1 (PCK1), altering its function so that it no longer primarily supports gluconeogenesis but instead facilitates tumor-associated metabolic reprogramming. Phosphorylated PCK1 promotes the phosphorylation of lactate dehydrogenase A (LDHA), thereby increasing lactate production and secretion. In our recent study, we identified lactylation of the SREBP regulating gene protein (SPRING) as a previously unrecognized metabolic adaptation mechanism in AKT-hyperactivated intrahepatic cholangiocarcinoma [170]. We found that elevated lactate levels induce SPRING lactylation at specific lysine residues, thereby enhancing activation of the SREBP cleavage-activating protein (SCAP)–sterol regulatory element-binding protein 2 (SREBP2) axis. This process promotes nuclear translocation of SREBP2 and transcriptional activation of mevalonate pathway genes. Increased mevalonate pathway activity subsequently enhances the synthesis of cholesterol, isoprenoid intermediates and antioxidant molecules, including coenzyme Q and menaquinone-4, which contribute to membrane lipid redox homeostasis [170]. However, these findings were obtained mainly from intrahepatic cholangiocarcinoma models, and their applicability to other tumour types requires further validation. These antioxidants substantially buffer lipid peroxidation, thereby suppressing ferroptosis, while also reducing the oxidative stress induced by chemotherapy and immunotherapy, ultimately enabling tumor cells to acquire chemo-immunotherapy resistance. Thus, when BMAL1 dysregulation leads to AKT hyperactivation, a metabolic protective axis—pPCK1–pLDHA–SPRINGlac–SREBP2–mevalonate—is established, forming a metabolic barrier against ferroptosis and therapeutic stress. These findings underscore the essential role of the circadian clock in maintaining CSC phenotypes. Therapeutically, targeting core clock components may provide a novel avenue to eliminate CSCs. For instance, pharmacological inhibition of BMAL1 or CLOCK, or activation of PER2 and CRY1, could rewire the transcriptional and metabolic circuits that sustain CSC identity, thereby impairing tumor progression and enhancing treatment efficacy. Circadian clock regulation of tumor invasion and metastasis The circadian clock plays a pivotal role in regulating tumor cell invasion and metastasis through diverse mechanisms, including modulation of epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodeling, and the TIME. BMAL1 and CLOCK can directly or indirectly upregulate MMPs, thereby facilitating ECM degradation and promoting tumor cell migration [160, 171]. In breast cancer models, BMAL1 enhances the NF-κB–MMP9 signaling cascade, enabling tumor cells to penetrate the basement membrane and invade adjacent tissues, ultimately accelerating both local invasion and distant metastasis [172]. Recent studies have found that BMAL1 has a bidirectional effect in tumor invasion and metastasis; it suppresses EMT by binding to the TGFB1 promoter and inhibiting its transcription, thereby downregulating Sma and Mad related protein 2 (SMAD2)/Sma and Mad related protein 3 (SMAD3) signaling and preventing snail family transcriptional repressor 1 (SNAIL1) activation. Loss of BMAL1 enhances TGF-β/SMAD signaling and promotes tumor cell invasion [173]. In GBM, the CLOCK–BMAL1 complex upregulates the periostin (POSTN)–TANK-binding kinase 1 (TBK1) signaling axis, promoting neovascularization and release of immunosuppressive factors [126, 174]. This creates a permissive environment for tumor colonization at distant sites by ensuring nutrient supply and dampening antitumor immune responses. Furthermore, circadian repressors such as PER2 are often downregulated in metastatic tumors. The loss of PER2 unleashes pro-invasive pathways like β-catenin, triggering EMT and conferring stem-like properties that enhance metastatic colonization [148, 175]. Furthermore, we observed that tumor-associated fibroblasts (CAFs) participate in Bmal1-mediated regulation of tumor metastasis. Mechanistically, suppression of Bmal1 expression elevates plasminogen activator inhibitor-1 (PAI-1) levels, leading to increased levels of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). This cascade activates plasmin, which subsequently triggers TGF-β signaling, promoting fibrosis and the differentiation of CAFs into pro-metastatic myofibroblastic CAFs (myoCAFs). The accumulation of myoCAFs remodels the tumor microenvironment [176]. This ECM stiffening and stromal remodeling further facilitates tumor cell invasion and metastatic dissemination. Notably, BMAL1 expression is significantly reduced in colorectal cancer liver metastases [177], and tumor cells exposed to stress conditions such as hypoxia or acidosis further suppress BMAL1, reinforcing metastatic potential through a self-sustaining loop [178]. Taken together, the circadian clock orchestrates tumor invasion and metastasis not only by transcriptionally regulating pro-metastatic genes but also by reshaping the tumor microenvironment via angiogenesis and CAF activation. Clinically, circadian disruption—such as that induced by chronic sleep deprivation—has been shown to downregulate BMAL1 expression [179, 180], supporting a link between behavioral rhythms and metastatic risk. These insights highlight the therapeutic promise of rhythm-targeted interventions, suggesting that restoring circadian homeostasis or targeting specific clock components could serve as effective strategies to suppress tumor metastasis (Fig. 3). Circadian clock disruption impairs DNA repair and promotes genomic instability The circadian clock plays a fundamental role in maintaining genomic integrity by orchestrating the cell cycle, DNA damage response (DDR), and various DNA repair pathways. Disruption of circadian rhythms compromises these processes, resulting in the accumulation of unrepaired DNA lesions and increased genomic instability—hallmarks of tumor initiation and progression [94, 162, 181–186]. DNA repair efficiency is closely linked to circadian regulation, likely as an evolutionary adaptation to mitigate the genotoxic effects of solar ultraviolet radiation. Robust DNA repair at dusk counters UV-induced DNA damage accumulated during daytime exposure and is critical for chromatin homeostasis [187]. Circadian misalignment diminishes DNA repair capacity and sensitizes cells to mutagenic insults such as ionizing radiation or diethylnitrosamine (DEN), thereby increasing tumor susceptibility [162]. Core circadian clock genes are essential regulators of DDR signaling pathways. BMAL1 deficiency impairs P53-mediated cell cycle arrest, enabling propagation of DNA damage [188–190]. CRY1 and CRY2 modulate the ATM and Rad3-related kinase (ATR)-checkpoint kinase 1 (CHK1) pathway involved in single-strand DNA damage repair. Notably, CRY1 forms a circadian-dependent complex with triosephosphate isomerase (TIM) to promote ATR kinase activity and activate the downstream CHK1 pathway, enhancing ATR activation and downstream CHK1 phosphorylation, thereby promoting cellular resistance to UV-induced genotoxic stress [191]. Meanwhile, PER1 engages with the ataxia-telangiectasia mutated proteins (ATM)-checkpoint kinase 2 (CHK2) axis, contributing to the repair of DNA double-strand breaks [192]. Disruption of these mechanisms compromises DDR signaling fidelity and accelerates genomic instability. Furthermore, the circadian clock regulates rhythmic expression of key DNA repair enzymes. The rate-limiting nucleotide excision repair (NER) protein xeroderma pigmentosum group A (XPA) exhibits circadian oscillation governed by core clock components. Chronodisruption abolishes the rhythmic activity of NER and ATR pathways, reducing DNA repair efficiency and increasing mutational burden [193–195]. In a recent study, researchers found that the circadian clock protein BMAL1 collaborates with its partner protein CLOCK to directly promote the repair of DNA double-strand breaks (DSBs), thereby enhancing tumor cell chemoresistance. This study revealed a noncanonical function of the circadian clock machinery in regulating DNA damage responses in cancer cells. Upon the occurrence of DNA double-strand breaks, the kinase ATM phosphorylates BMAL1 at Ser183, activating it. The phosphorylated BMAL1 is recruited to sites of DNA damage and forms a complex with CLOCK, promoting histone H4 acetylation (H4Ac). This histone modification facilitates DNA end resection, generating single-stranded DNA (ssDNA) and thereby promoting the homologous recombination (HR) repair pathway. Cells lacking BMAL1 show defects in HR repair, leading to the accumulation of unrepaired DSBs and genomic instability [196]. Together, these findings underscore the essential role of the circadian system in safeguarding genomic stability. Loss of circadian regulation perturbs DNA repair fidelity and DDR execution, thereby fostering a permissive environment for oncogenesis. Targeting circadian components may thus represent a novel approach to enhance genomic stability and counteract tumor evolution. Circadian clock regulation of tumor angiogenesis Angiogenesis is a key determinant of solid tumor development, facilitating nutrient supply, oxygen delivery, and metastatic dissemination. Tumor cells secrete pro-angiogenic factors such as hypoxia-inducible factor-1α (HIF-1α), aryl hydrocarbon receptor nuclear translocator (ARNT), and vascular endothelial growth factor (VEGF), whose expression is tightly regulated by the circadian clock [197]. The circadian system governs angiogenic signaling through transcriptional regulation of key pro-angiogenic genes. The transcriptional activators BMAL1 and CLOCK promote tumor neovascularization by upregulating VEGF. In glioblastoma models, the CLOCK–BMAL1 complex enhances POSTN expression by activating downstream targets such as olfactomedin-like protein 3 (OLFML3) and HIF-1α, which in turn stimulate TBK1 signaling in endothelial cells to drive angiogenesis [174]. Inhibition of the CLOCK–POSTN–TBK1 axis significantly suppresses tumor vascularization and growth, identifying it as a promising anti-angiogenic target. BMAL1 also functions intrinsically within endothelial cells to regulate vascular development. It controls the expression of cell cycle–related genes such as cyclin A1 (CCNA1) and cyclin-dependent kinase 1 (CDK1), thereby promoting endothelial proliferation and new vessel formation. Endothelial-specific deletion of BMAL1 in mouse models results in impaired tumor angiogenesis and reduced tumor burden, highlighting its cell-autonomous role in vascular remodeling [198]. Circadian control of VEGF further contributes to time-of-day–dependent angiogenic activity. Under hypoxic conditions, VEGFA expression follows circadian oscillations regulated by BMAL1 and CLOCK through indirect modulation of HIF-1α [199]. Notably, VEGFA upregulation in response to anti-angiogenic therapy is associated with treatment resistance. Studies have shown that BMAL1 expression increases upon anti-angiogenic drug administration, correlating with compensatory VEGF elevation and reduced therapeutic efficacy [200]. In summary, the circadian clock modulates tumor angiogenesis via transcriptional and post-transcriptional control of key pro-angiogenic mediators. These findings implicate circadian dysregulation as a contributor to angiogenic plasticity and therapeutic resistance. Chronotherapy strategies that align drug administration with circadian rhythms or target core clock components may enhance anti-angiogenic treatment efficacy and circumvent resistance mechanisms. Circadian clock regulates metabolic reprogramming in tumors The circadian system plays a critical role in tumor initiation and progression by orchestrating tumor cell glucose metabolism and modulating acidification of the TIME. Core clock genes tightly regulate the transcription of glycolytic enzymes and transporters, thereby shaping the metabolic phenotype of cancer cells. Disruption of circadian rhythms—due to factors such as light-at-night exposure or shift work—leads to aberrant expression of these genes, enhancing glycolytic flux and promoting tumor cell proliferation, invasiveness, and metabolic plasticity [201]. In addition to its direct metabolic effects, the circadian clock indirectly influences acid–base homeostasis within the TIME by modulating gut microbiota composition and function. Diurnal fluctuations in gut microbial communities impact host metabolism and immune tone, ultimately altering the local pH environment of tumors. Commensal bacteria—particularly Firmicutes—ferment dietary fibers into SCFAs, such as butyrate and propionate, which enter systemic circulation and accumulate in tumor tissues. Under hypoxic conditions, these metabolites, along with lactate produced via aerobic glycolysis, are further metabolized by tumor and immune cells, contributing to microenvironmental acidification. This acidic niche suppresses cytotoxic T cell function and enhances the activity of immunosuppressive cell populations, including Tregs and TAMs, thereby facilitating immune evasion and tumor progression [56, 202–204]. Moreover, gut microbiota depletion has been shown to impair central circadian clock function and disrupt rhythmic secretion of neuroendocrine factors such as glucocorticoids [49], further weakening tumor immune surveillance and exacerbating TIME acidification. Under hypoxic conditions characteristic of solid tumors, BMAL1 regulates HIF-1α stability and activity, and modulates its accumulation [205]. BMAL1-mediated stabilization of HIF-1α drives transcriptional upregulation of key glycolytic enzymes and transporters, including GLUT1/3, HK1/2, LDHA, and MCT4 [206–213], thereby enhancing the Warburg effect and contributing to extracellular acidification. In parallel, BMAL1 regulates pyruvate kinase muscle isozyme M2 (PKM2) expression in macrophages, which, in combination with lactate levels, governs programmed death-ligand 1 (PD-L1) expression. This BMAL1–PKM2–PD-L1 axis plays a pivotal role in suppressing anti-tumor immunity and mediating resistance to immune checkpoint blockade [214] (Fig. 4). Circadian control of energy metabolism in tumor cells. The circadian clock regulates the rhythmic availability of nutrients and metabolic intermediates, driving time-of-day-dependent preferences for glycolysis versus oxidative phosphorylation, leading to oscillatory ATP production. In tumors, circadian disruption supports a glycolysis-dominant metabolic reprogramming (Warburg effect) that fuels rapid proliferation and immune evasion via lactate accumulation. Clock components modulate key metabolic enzymes: ROR suppresses glycolysis through G-6-PD inhibition; PER1 influences glycolytic flux and therapy responsiveness via hexokinase 2 (HK2); and BMAL1 coordinates hypoxic adaptation via HIF-1α, a key BMAL1 target highly expressed in tumors. Additionally, the clock promotes glycolysis, fatty acid synthesis, and the pentose phosphate pathway to meet bioenergetic and biosynthetic demands while reprogramming the TIME to suppress T cell function and enhance Treg infiltration. These mechanisms support targeting circadian regulators as a novel strategy for metabolic intervention in cancer Collectively, the circadian system orchestrates tumor cell glucose metabolism, acidification of the TIME, and immune evasion through multifaceted mechanisms, thereby influencing tumor initiation, progression, and therapeutic resistance. Restoration of circadian homeostasis has the potential to suppress the Warburg effect and mitigate immune escape, presenting promising strategies for cancer prevention and metabolic-targeted therapies. Multiple transcriptional regulators involved in metabolic control exhibit circadian oscillations driven by the autonomous molecular clock. These include PAR bZIP transcription factors (DBP, TEF, and HLF), as well as their repressors NFIL3/E4BP4 and KLF10/mGIF/TIEG1 [215–217]. At both transcriptional and post-transcriptional levels, the circadian clock regulates rhythmic expression of key glucose metabolism genes—including glucagon receptor, glucose transporters, and pyruvate kinase—with expression peaks aligned to anticipatory feeding windows [218]. This coordination promotes efficient glycogen storage and glucose utilization, synchronizing cellular energy metabolism with feeding–fasting cycles and enhancing insulin sensitivity, glucose uptake, and energy substrate switching [219]. Major nutrients and their associated metabolic intermediates also display strong circadian rhythmicity, with time-of-day-dependent preferences for oxidative versus glycolytic ATP generation [220]. In cancer cells, this rhythmic regulation is often co-opted to favor aerobic glycolysis (the Warburg effect), a hallmark of tumor metabolism that supports rapid proliferation, immune evasion, and drug resistance—largely through lactate accumulation and acidification of the TIME [221]. Consequently, targeting tumor energy metabolism is a critical and promising therapeutic strategy, with abundant evidence supporting robust circadian regulation of key metabolic pathways involved in tumor energetics, including: (1) ROR-mediated suppression of glucose-6-phosphate dehydrogenase (G-6-PD), inhibiting tumor glycolysis and proliferation [133]; (2) PER1 regulation of HK2-dependent glycolysis in tumor cells, impacting targeted therapy responses [222]; (3) BMAL1-dependent HIF-1α regulation of anaerobic glycolysis [223, 224]. Given the high metabolic demands and pervasive hypoxia in solid tumors, HIF-1α is frequently overexpressed and critically influences tumor metabolism, immune suppression, and overall tumor aggressiveness. Notably, BMAL1 has emerged as a potent upstream regulator and potential therapeutic target in this context. These insights underscore the potential of circadian-targeted strategies to reprogram tumor metabolism and improve clinical outcomes (Fig. 4). Interestingly, while the autonomous circadian clock generally enhances rhythmic gene expression and metabolic homeostasis, it can also attenuate the oscillatory amplitude in some contexts. For instance, CRY1/2 knockdown increases redox oscillation amplitude, triggering oxidative stress and metabolic imbalance. Conversely, BMAL1 knockdown paradoxically induces rhythmicity in glycolytic metabolites, suggesting adaptive shifts in energy metabolism [24]. Importantly, tumor-intrinsic circadian clocks support malignant growth and survival by regulating metabolic fluxes—including enhanced glycolysis, fatty acid synthesis, and activity of the pentose phosphate pathway, which fuels nucleotide biosynthesis and redox balance [225–227]. These metabolic reprogramming events not only sustain rapid proliferation but also reshape the TIME, impairing cytotoxic T cell activity and promoting the accumulation of immunosuppressive populations such as Tregs. Elevated lactate concentrations, in particular, serve as key mediators of immunosuppressive signaling and tumor immune escape. Circadian clock regulates pro-tumor inflammation Overexpression of NR1D1 in ovarian cancer cells has been shown to upregulate suppressor of cytokine signaling 3 (SOCS3), a key negative regulator of the JAK/STAT signaling pathway. By increasing SOCS3 levels, REV-ERBα effectively reduces the phosphorylation of JAK and STAT3, thereby dampening STAT3-mediated transcriptional activity. This suppression leads to a decrease in tumor-associated inflammatory responses, including the production of pro-inflammatory cytokines such as IL-6 and IL-10, and limits the recruitment or polarization of immunosuppressive cells within the tumor microenvironment [228]. Through this mechanism, REV-ERBα functions as a negative regulator of JAK/STAT3-driven tumor-promoting inflammation, highlighting its potential as a therapeutic target to modulate inflammation and tumor progression in ovarian cancer. Endogenous rhythms regulate cancer cell biological behavior Neuroendocrine rhythms exert profound effects on cancer cell biology, modulating proliferation, apoptosis, metabolism, and invasiveness through circadian fluctuations in hormones, neurotransmitters, and cytokines. Melatonin, which peaks during the night, acts as a potent inhibitor of cancer cell proliferation and glucose/lipid metabolism. Circadian disruption, such as exposure to light at night, suppresses melatonin production, thereby facilitating tumor growth [201]. Similarly, circadian oscillations in hormones like IGF-1 and cortisol closely regulate tumor cell proliferation and survival. IGF-1, primarily secreted by the liver under growth hormone stimulation, peaks nocturnally. The binding of IGF-1R activates downstream PI3K/AKT and MAPK signaling pathways, which promote cell proliferation and inhibit apoptosis. Disruption of IGF-1 rhythmicity—commonly observed in shift work or nighttime light exposure—leads to sustained pathway activation, enhancing tumor progression [229]. Cortisol, a glucocorticoid hormone secreted by the adrenal cortex under hypothalamic-pituitary-adrenal (HPA) axis regulation, exhibits a circadian peak in the early morning followed by a nocturnal decline. Cortisol influences gene expression and signaling cascades via binding to the glucocorticoid receptor (GR), affecting metabolism, cell proliferation, and apoptosis. Aberrant cortisol rhythms result in dysregulated GR signaling and hyperactivation of proliferative pathways such as AKT and p38 MAPK, significantly promoting tumor cell survival and growth [230]. As described previously, feeding–fasting cycles drive endogenous circadian fluctuations through mechanisms including gastric acid secretion and glucagon-mediated cAMP-PKA signaling, as well as insulin- and IGF-1-regulated AKT-mTOR pathways. Concurrently, mTOR signaling upregulates oncogene expression and modulates levels of the core clock gene PER2. Aberrant activation of mTOR in tumor cells suppresses apoptosis while enhancing proliferation and angiogenesis [231, 232]. Furthermore, elevated cAMP-PKA signaling promotes tumorigenic events such as DNAJB1-PRKACA fusion, BAP1 mutations, alterations in TIME dopamine and Prostaglandin E2 (PGE2) signaling, and activating mutations in GNAS, collectively driving tumor initiation and progression [232–238]. Therefore, endogenous rhythmic changes induced by feeding behavior critically influence tumor evolution and remodeling of the TIME, highlighting the intricate interplay between metabolic rhythms and cancer biology. Circadian clock regulates TIME remodeling Beyond cancer incidence, circadian regularity appears to influence cancer progression. Patients with colorectal cancer who maintain more consistent circadian behaviors—including regular sleep, activity, and feeding patterns—exhibit improved prognoses and quality of life [239–241]. Collectively, these epidemiological findings underscore the vital role of the circadian clock not only in cancer risk and progression, but also in shaping tumor immunity (Fig. 5). Circadian clock-mediated remodeling of the TIME. The cell-autonomous circadian clock is generated by transcription–translation feedback loops (TTFLs) involving CLOCK and brain and muscle ARNT-like 1 (BMAL1), which govern the circadian oscillation of immune cell metabolism and function. The circadian clock modulates IL-6 and TNF-α levels within the TIME, thereby regulating the activation of the JAK/STAT and NF-κB signaling pathways. These regulatory effects reshape immune surveillance by influencing macrophage polarization, T cell exhaustion, and dendritic cell (DC) maturation. Moreover, the circadian clock directly regulates chemokine expression on endothelial cells, macrophages, and CD4⁺ T cells, thereby affecting the infiltration of myeloid-derived suppressor cells (MDSCs), tumor angiogenesis, and macrophage polarization, collectively contributing to the dynamic remodeling of TIME Studies in breast cancer and melanoma mouse models have demonstrated that silencing the tumor cell circadian clock increases the proportion of Tregs. Tregs secrete immunosuppressive cytokines such as transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), which induce macrophage polarization toward an immunosuppressive M2 phenotype [242]. This shift leads to reduced infiltration and activity of CD8+ T cells, thereby promoting an immunosuppressive TIME [113, 168]. Pan-cancer analyses reveal a strong correlation between immune infiltration in the TIME and the status of the tumor cell circadian clock. However, this correlation varies considerably across different cancer types. Circadian clock suppression has been linked to T cell exhaustion [243, 244]. Preliminary bioinformatic analyses suggest that this phenomenon may depend on the heterogeneity of immune infiltration within the TIME from different tissue origins (Fig. 5). Reprogramming of the circadian clock in advanced tumors In the hypoxic microenvironment of advanced cancers, elevated HIF-1α disturbs the rhythmic expression of PER2, altering metabolic and cell cycle regulation [245]. Additionally, tumor-derived lactate accumulates in the TIME, leading to acidic conditions that suppress circadian clock gene expression in both tumor and immune cells through lactate-mediated signaling, thereby disturbing tissue-level rhythms [246]. Moreover, immune cells can modulate circadian homeostasis via inflammatory signaling. TAMs and MDSCs release high levels of interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α) and IL-10, which activate pathways including Janus kinase (JAK)-STAT and NF-κB, altering core clock gene expression and reprogramming immune cell temporal rhythms [247–253]. These disruptions contribute to impaired immune cell functionality, particularly CD8⁺ T cell exhaustion, which is often accompanied by downregulation of circadian genes within the TIME [254–257]. Attenuated circadian responsiveness weakens immune surveillance and reduces immunotherapeutic efficacy, thereby promoting immune escape [11, 243, 258]. Collectively, these findings illustrate a “bidirectional disruption” wherein advanced tumors evade immune control while concurrently perturbing systemic circadian regulation. This reciprocal interference not only shapes tumor biology but also significantly alters the host antitumor immune response and therapeutic sensitivity. Circadian clock regulates immune cells in tumors The circadian clock within the TIME influences immune surveillance and tumor immune suppression by modulating immune cell functional states, thereby affecting tumor growth and metastasis. The quantity, migration, infiltration, phenotype, and immune activity of immune cells in both the host and TIME are highly correlated with circadian phases [259, 260], thereby determining the time-dependent nature of antitumor immunity [158] (Fig. 6). Circadian regulation of immune cells within the TIME. The circadian clock orchestrates the function and polarization of multiple immune cell subsets in the TIME. In TAMs, CLOCK promotes M2 polarization and immunosuppressive activity via the HIF1α–LGMN axis. BMAL1 maintains mitochondrial homeostasis and restricts M1 polarization and reactive oxygen species (ROS) production, while its loss enhances inflammatory cytokine expression and macrophage activation. REV-ERBα suppresses chemokine (C-C motif) ligand 2 (CCL2), limiting pro-inflammatory responses and favoring M2 phenotypes. Th17 differentiation depends on both Retinoic acid–related orphan receptor (ROR) α and RORγ; their absence skews differentiation toward the Treg lineage. Rhythmic expression in DCs regulates their ability to prime CD8⁺ T cells, and loss of clock genes impairs anti-PD-1 responses. CD8⁺ T cell infiltration, IFN-γ and Granzyme B (GZMB) expression, and mechanistic target of rapamycin (mTOR) signaling all exhibit circadian rhythms, regulated by CLOCK and BMAL1. PD-1 expression also varies diurnally, linking circadian control to immune checkpoint blockade efficacy. CD4⁺ T cells display time-dependent immune regulation, while Tregs, though lacking an intrinsic clock, respond to external circadian cues. Natural killer (NK) cell cytotoxicity and effector gene expression are highly circadian-dependent and require a functional clock. Together, these findings highlight the critical role of the circadian system in regulating immune cell activity in TIME and suggest chrono-immunotherapy as a promising therapeutic paradigm Tumor-Associated Macrophages (TAMs) Functional circadian clocks are present in TAMs [261], and numerous aspects of macrophage biology—including reactive oxygen species (ROS) levels, cytokine expression such as interleukin-1 (IL-1), and various bioenergetic metabolic pathways—are extensively regulated by the circadian clock [262]. The circadian clock plays a critical role in directing macrophage polarization, shaping their functional states within the TIME. Core clock genes regulate macrophage metabolic activity, inflammatory cytokine expression, and chemotaxis, determining polarization toward pro-inflammatory M1 or immunosuppressive M2 phenotypes [262]. The CLOCK protein is stably expressed in TAMs and regulates the HIF1α-LGMN axis to promote M2 polarization. CLOCK’s rhythmic regulation enhances VEGFA and arginase 1 (ARG1) expression, fostering an immunosuppressive microenvironment. Specifically, CLOCK upregulates HIF1A transcription in tumor stem cells, which activates downstream target legumain (LGMN). LGMN induces the chemokine CD162, facilitating recruitment and polarization of immunosuppressive macrophages, thereby creating an “immune cold” tumor milieu. Targeted intervention of the CLOCK-HIF1α-LGMN axis effectively alleviates this immunosuppression and enhances CD8⁺ T cell tumor infiltration and antitumor activity. Combination therapy with immune checkpoint inhibitors such as anti-PD-1 antibodies demonstrates significant synergistic effects in murine models [263]. The circadian protein BMAL1 in macrophages not only governs the biological clock but also coordinates mitochondrial metabolism and immune activation. BMAL1 maintains mitochondrial function and metabolic homeostasis, influencing macrophage immune responses through mitochondrial metabolism, ROS generation, and cytoskeletal remodeling, thereby restricting M1 polarization under inflammatory stimuli. BMAL1-deficient macrophages exhibit mitochondrial dysfunction and metabolic reprogramming, resulting in aberrant upregulation of pro-inflammatory factors and enhanced M1 polarization [264]. These findings suggest that targeting BMAL1 may represent a novel strategy to bolster immune surveillance [265]. Additionally, BMAL1 suppression increases macrophage sensitivity to inflammatory stimuli (e.g., LPS), leading to excessive release of IL-1β, TNF-α, and other pro-inflammatory cytokines [266]. REV-ERBα negatively regulates the pro-inflammatory chemokine CCL2, significantly inhibiting macrophage inflammatory responses and migration, thereby limiting M1 polarization while promoting M2 phenotype formation. REV-ERBα also affects macrophage recruitment to inflamed sites. REV-ERBα/β agonists suppress MDSCs and M2 macrophages, improving the immunosuppressive TIME. Mechanistically, REV-ERBα, as a repressive nuclear receptor, binds the CCL2 promoter region to block recruitment of pro-inflammatory transcription factors and repress CCL2 expression. This regulation exhibits circadian rhythmicity, indicating that macrophage inflammatory activity is finely tuned by the biological clock [267]. These insights offer potential strategies for targeting REV-ERBα to modulate macrophage function and tumor immune suppression. In conclusion, evidence indicates that core circadian transcriptional regulators—CLOCK, BMAL1, and REV-ERBα—control macrophage polarization and immune microenvironment remodeling, profoundly influencing the immunosuppressive state of the TIME. Sleep-wake cycles, feeding behaviors, glucose metabolism, body temperature, glucocorticoids, insulin, glucagon, and other endocrine factors can target the circadian clock. Notably, REV-ERBα is highly sensitive to these factors. Therefore, circadian clock regulation of macrophage polarization and immune microenvironment remodeling presents important temporal biological intervention strategies for tumor immunotherapy. Th17 cells Th17 differentiation and survival critically depend on circadian clock core components including RORα, RORγ, and CLOCK [268, 269]. RORα and RORγ are essential regulators of Th17 cell differentiation and antitumor immunity [268], underscoring the central role of circadian regulators in shaping immune cell functionality and influencing tumorigenesis. RORγ, particularly its isoform RORγt, is a key transcription factor driving Th17 differentiation. RORα is highly expressed in Th17 cells, induced by TGF-β and IL-6 via STAT3 signaling. RORα overexpression promotes Th17 differentiation and markedly upregulates IL-17 and IL-17F. Co-expression of RORα and RORγ synergistically enhances Th17 differentiation in vitro and in vivo. Dual RORα/γ knockout mice almost completely lack Th17 cells, demonstrating their non-redundant essential roles in Th17 lineage specification [268]. Further studies show that RORγt is selectively expressed in Th17 versus Th1, Th2, or Treg subsets, essential for CD4⁺ T cell production of IL-17 and IL-17F. RORγt deficiency disrupts Th17 differentiation, drastically reducing cytokine expression and secretion. TGF-β and IL-6 induce RORγt expression, representing critical signals for Th17 induction. Thus, RORγt is a pivotal determinant of Th17 lineage fate [270], providing novel targets for modulating tumor immune responses. Recent work also confirms the independent role of RORα in Th17 differentiation and function. RORα deficiency significantly reduces IL-17A expression, decreasing pro-inflammatory Th17 cell frequency and increasing immunosuppressive Foxp3⁺ regulatory T cells. This shift promotes the TIME transition from immune activation to immunosuppression, reducing local pro-inflammatory cytokines and antigen presentation, and substantially impairing effector CD8⁺ T cell function. Consequently, anti-tumor immune surveillance is weakened, favoring tumor growth, metastasis, immune evasion, and reduced immunotherapy efficacy [271]. Dendritic cells (DCs) Both DC abundance and expression of T cell costimulatory molecules display circadian clock–dependent rhythms. DCs exhibit differential activity across the day, with enhanced T cell activation capacity at night. This rhythmic regulation is primarily mediated by the circadian gene BMAL1, which modulates costimulatory molecules such as CD80, thereby affecting CD8⁺ T cell proliferation and cytotoxicity and driving circadian rhythmicity in tumor immunity. Disruption of the DCs’ circadian clock in animal models significantly impairs immune checkpoint blockade (ICB) efficacy, such as anti-PD-1 therapy, confirming the critical impact of DCs’ circadian regulation on immunotherapy outcomes [119, 158]. CD8⁺ T cells Core circadian clock genes have been shown to critically modulate the cytotoxic activity of CD8⁺ T cells. BMAL1 deficiency leads to reduced CD8⁺ T cell numbers and promotes tumorigenesis [113]. However, conditional deletion of the BMAL1 gene specifically in CD8⁺ T cells does not significantly alter their total numbers but impairs their responsiveness to antigenic stimulation. Notably, the circadian rhythmicity of CD8⁺ T cell responses to antigen presentation is abolished, accompanied by reduced IFN-γ production, underscoring the critical role of BMAL1 in maintaining CD8⁺ T cell function and circadian responsiveness [272]. Moreover, disruption of circadian rhythms promotes the accumulation of MDSCs, which in turn suppress CD8⁺ T cell proliferation and function, leading to an immunosuppressive state [113, 273]. Loss of BMAL1 protein results in the loss of rhythmic expression of IFN-γ and GZMB in T cells [274, 275], while CLOCK protein participates in the circadian regulation of the mTOR pathway, influencing T cell proliferation and memory formation. In other words, BMAL1 silencing within CD8⁺ T cells significantly compromises their antitumor capacity, evidenced by accelerated tumor progression and decreased expression of T cell effector molecules such as IFN-γ and granzyme B (GZMB). Importantly, pharmacological activation of the mTOR pathway partially rescues the immune dysfunction caused by BMAL1 deficiency [258]. These findings identify BMAL1 as a pivotal regulator of T cell metabolism and translational efficiency, highlighting its potential therapeutic significance in modulating tumor immunity and suggesting the BMAL1/mTOR axis as a promising target to enhance T cell-mediated antitumor responses. CD8⁺ T cell infiltration in the tumor microenvironment exhibits pronounced circadian rhythmicity, driven by the time-dependent migration of tumor-infiltrating lymphocytes (TILs) from blood to tumor tissue. This rhythm is regulated by the circadian clock of tumor vascular endothelial cells, which controls the rhythmic expression of ICAM-1 [274]. Thus, the endothelial circadian clock in the tumor microenvironment orchestrates the temporal abundance of CD8⁺ TIL infiltration. As CAR T cell therapy relies heavily on the migration and infiltration of CD8⁺ T cells into tumor tissue, its therapeutic efficacy shows significant time dependency, which has been validated in animal models [11]. Genes involved in leukocyte adhesion and T cell activation within tumor-infiltrating CD8⁺ T cells also display significant circadian oscillations, indicating cyclic activation and suppression states in their antitumor immune activity. Furthermore, the immune checkpoint PD-1 exhibits robust circadian rhythmic expression in tumor-infiltrating CD8⁺ T cells, which is abolished and maintained at low levels when the circadian clock is disrupted, demonstrating that the CD8⁺ T cell intrinsic clock drives periodic upregulation of PD-1 [11]. Given that CD8⁺ T cells are the primary effectors in tumor cell killing and the main targets of current immunotherapies, their quantity and functional status within the TIME are crucial for effective immune surveillance and tumor immunotherapy. Indeed, the time-dependent efficacy of ICIs has been confirmed across multiple tumor animal models [119, 276]. CD4⁺ T cells CD4⁺ T cells, as a major component of TILs, exhibit rhythmic infiltration patterns into the TIME, which are tightly regulated by the circadian clock of tumor vascular endothelial cells. This endothelial clock drives oscillatory expression of ICAM-1, thereby modulating the time-dependent recruitment of CD4⁺ T cells and other TIL subsets [11, 277–279]. Intrinsic circadian clocks within CD4⁺ T cells govern their differentiation trajectory, dictating functional polarization and the dynamic balance between immune activation and suppression in the TIME. Core clock components modulate key immunological processes, including cytokine secretion, metabolic reprogramming, and fate determination. Th1 cells demonstrate circadian oscillations in IFN-γ production, critical for antitumor cytotoxicity [280, 281]. Meanwhile, Tregs are rhythmically influenced by systemic oscillations in cortisol, IL-2, and TGF-β, which fine-tune their suppressive capacity, thereby providing a feedback mechanism to maintain immune homeostasis within the TIME. Collectively, CD4⁺ T cells serve as pivotal regulators bridging effector and regulatory immunity, their function shaped by a confluence of cell-autonomous clocks and systemic circadian cues. Regulatory T cells (Tregs) Tregs predominantly maintain immune tolerance and suppress antitumor immune responses within tumors, constituting a central axis of tumor immune evasion. Unlike other immune cells in the TIME, Tregs lack a robust intrinsic circadian oscillator. However, they exhibit rhythmic immunosuppressive functions driven by extrinsic circadian signals, which modulate macrophage activity and immune suppression in a temporal manner [282]. Notably, loss of the nuclear receptor RORα leads to an increased frequency of Foxp3⁺ immunosuppressive Tregs [271], promoting a shift in the TIME from an immune-activated to an immunosuppressive state. NK cells NK cells are critical cytotoxic effectors in antitumor immunity, capable of recognizing and lysing tumor cells directly. They also secrete key cytokines such as IFN-γ that facilitate recruitment and activation of additional immune effectors. The expression of NK cell cytolytic molecules, including GZMB and perforin, and cytokines IFN-γ and TNF-α is tightly controlled by the cell-intrinsic circadian clock. This regulation leads to pronounced circadian rhythms in NK cell cytotoxic activity, with maintenance of functional cytolytic capacity reliant on intact circadian clock mechanisms [283, 284]. Myeloid-Derived Suppressor Cells (MDSCs) The circadian clock exerts multifaceted regulation over MDSCs, which play critical roles in fostering immune suppression within the TIME. MDSCs encompass two principal subsets—monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC)—that facilitate tumor immune escape by suppressing T cell responses, promoting Treg expansion, and releasing immunosuppressive mediators such as ARG1, nitric oxide (NO), and ROS. Both MDSC abundance and suppressive function oscillate in a circadian manner under the control of core clock genes. The nuclear receptor REV-ERBα modulates MDSC metabolism, regulating fatty acid oxidation and lactate processing, which directly impacts their immunosuppressive capacity. Circadian disruption exacerbates MDSC infiltration and immunosuppressive activity within tumors, thereby intensifying antitumor immune suppression [273, 285]. In addition, tumor-secreted factors including granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-6 exhibit circadian secretion patterns that further regulate MDSC generation and activation. Circadian control of adhesion molecules on tumor vasculature influences MDSC trafficking and spatial localization in the TIME. Crucially, MDSCs require intact circadian gene expression to respond appropriately; clock dysfunction results in increased MDSC frequency and enhanced T cell suppressive potency. Overall, the circadian clock intricately shapes MDSC development, metabolism, and function, reinforcing the immunosuppressive milieu of the TIME. Circadian clock regulated innate immune monitoring Disruption of circadian clock weakens innate immune surveillance Circadian rhythms govern the development, trafficking, and functional activity of various immune cells, including NK cells, macrophages, and neutrophils [241], as well as the rhythmic expression of cytokines and immunoregulatory molecules including IFN-γ, IL-2 and TNF-α within the TIME [113, 286]. Circadian disruption induced by factors such as sleep deprivation or sleep-wake cycle inversion can impair cytotoxic T cell responses and immune surveillance, ultimately increasing cancer risk [110]. The circadian clock orchestrates macrophage polarization, impacting its functional state and immunosuppressive roles within the TIME. Core clock components regulate macrophage metabolic reprogramming, cytokine expression, and chemotactic responses, collectively dictating the balance between pro-inflammatory M1 and immunosuppressive M2 phenotypes [264]. REV-ERBα, in particular, negatively regulates pro-inflammatory chemokines such as C-C motif chemokine ligand 2 (CCL2), thereby limiting M1 polarization and promoting M2 phenotype formation. Pharmacological activation of REV-ERBα/β suppresses MDSCs and M2 macrophages, alleviating immunosuppressive TIME [287]. Disruption of clock genes also sensitizes macrophages to inflammatory stimuli (e.g., lipopolysaccharide (LPS)), triggering excessive release of IL-1β, TNF-α, and other cytokines [266, 288]. MicroRNAs (miRNAs) play pivotal roles in the rhythmic transcriptional regulation of tumor immunity. Numerous miRNAs, including Let-7, miR-155, miR-33, and miR-103, display robust circadian expression patterns [289]. These miRNAs regulate key metabolic factors and processes such as insulin sensitivity, glucose homeostasis, and lipid metabolism, as well as immune functions such as cytotoxicity and secretion. For instance, miR-155 directly targets the circadian protein BMAL1 to modulate macrophage immune function. Under inflammatory stimuli, macrophages upregulate miR-155 expression, which inhibits BMAL1, disrupts circadian homeostasis, amplifies inflammatory responses, and promotes M1 polarization. Animal models further confirm that miR-155-mediated suppression of BMAL1 alters macrophage cytokine production and circadian immune rhythmicity, ultimately impairing temporal coordination of immune responses [290]. By regulating immune cells in the TIME, clock genes influence the temporal dynamics and efficiency of tumor immunity, as well as immune checkpoint molecule expression. Aberrant expression of circadian genes such as BMAL1, CLOCK, and PER1 is closely correlated with upregulation of immune checkpoints including PD-L1, PD-1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [243], thereby modulating immune surveillance and immunotherapy responses [132] (Fig. 5). The functional state of immune cells largely depends on their metabolic processes. For immune cells like NK cells, neutrophils and macrophages, metabolic status determines their propensity to maintain immune tolerance or mediate immune attack. Studies indicate that immune cell metabolic pathways exhibit periodic fluctuations governed by circadian rhythms. For instance, activation and proliferation of immune cells show elevated metabolic demands during specific circadian peaks, correlating closely with their requirements for glucose, fatty acids, and other substrates. BMAL1 is upregulated in macrophages upon inflammatory stimuli (e.g., LPS or IFN-γ) to maintain mitochondrial integrity and function. Meanwhile, metabolites from immune and tumor cell metabolic pathways, such as the pentose phosphate pathway and anaerobic glycolysis, feedback to regulate circadian clock transcription factors by modulating their transcriptional activity and DNA binding, thereby influencing the amplitude and progression of autonomous circadian cycles [225, 226]. This establishes a tight interplay between the circadian clock system and tumor immunity–related metabolic processes that collectively shape the immune status within the TIME. Alterations in the circadian clock system can lead to metabolic reprogramming that facilitates immune evasion mechanisms. Under inflammatory stimulation (e.g., LPS), BMAL1-deficient macrophages exhibit impaired mitochondrial metabolism characterized by increased glucose uptake and glycolytic activity, particularly marked by aberrantly elevated succinate dehydrogenase (SDH) activity. This results in the accumulation of succinate within the TCA cycle and excessive mitochondrial reactive oxygen species (mROS) production. The generated ROS stabilize HIF-1α, triggering metabolic reprogramming that enhances IL-1β expression and skews macrophages toward a glycolytic and pro-inflammatory phenotype. Simultaneously, stabilized HIF-1α promotes expression of immunosuppressive factors, ultimately contributing to an immunosuppressive TIME driven by immune exhaustion and other factors. Moreover, BMAL1 regulates the levels and localization of the glycolytic enzyme PKM2, which further activates the signal transducer and activator of transcription 3 (STAT3) pathway, increasing Il1b mRNA transcription. A murine melanoma model demonstrated that BMAL1 deficiency in macrophages enhances tumor growth, an effect reversible by SDH inhibition with agents such as dimethyl malonate [264]. Collectively, these data highlight BMAL1 as not only a core circadian regulator but also a pivotal molecular link connecting immunity, metabolism, and inflammatory responses [288]. Current evidence suggests that the BMAL1-HIF axis functions as a crucial bridge connecting circadian rhythms, immunity, and metabolism in the hypoxic microenvironment of solid tumors, representing an important “immunometabolic regulatory hub” within the TIME [205, 223, 266, 291, 292]. Given the circadian clock system’s influence on immune cell and tumor cell metabolism and the regulation of tumor immune processes and states in the TIME, it likely impacts immunotherapy outcomes. Targeting BMAL1 and its downstream metabolic pathways to achieve temporally precise intervention of macrophage-mediated inflammation holds significant promise for modulating tumor immune status. The circadian clock regulates the adaptive immune surveillance of killing cancer cells Antigen presentation and T cell activation and expansion The circadian clock significantly impacts the antigen presentation process within tumor immunity by regulating the function and distribution of immune cells. DCs, as key antigen-presenting cells, exhibit circadian regulation in their differentiation, migration, maturation, and antigen presentation capacity. BMAL1 expression in DCs displays rhythmicity, modulating their migration between peripheral tissues and lymph nodes, thereby influencing the timing and efficiency of tumor antigen uptake and presentation to T cells. BMAL1 regulates the expression of C-C motif chemokine ligand 21 (CCL21), chemokine receptor C-C chemokine receptor type 7 (CCR7), and lymphatic vessel marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), which collectively orchestrate the circadian migration of DCs to lymphatic vessels. Loss of BMAL1 disrupts the circadian migration rhythm of DCs, impairing their antigen-presenting function [293]. Furthermore, BMAL1’s rhythmic expression in DCs controls the expression of the costimulatory molecule CD80, which affects T cell activation [119]. These findings suggest that specific temporal windows exist during which the immune system is more proficient at recognizing and initiating anti-tumor responses. T cell activation depends on the recognition of antigen-MHC complexes by the T cell receptor (TCR), costimulatory signals, and cytokine-mediated synergy. Circadian factors BMAL1 and CLOCK regulate the expression and activation status of key signaling molecules within the TCR pathway, including nuclear factor of activated T-cells (NFAT) and NF-κB, thereby modulating T cell sensitivity and responsiveness to antigenic stimulation [253, 258, 294] (Fig. 7). Circadian regulation of tumor immune responses. The circadian clock modulate the function of DCs and T cells, thereby influencing antigen presentation, T cell priming, migration, and cytotoxic activity. BMAL1 governs the diurnal migration of DCs, costimulatory molecule expression, and antigen presentation efficiency, which are critical for T cell activation. In T cells, CLOCK and BMAL1 regulate T cell receptor (TCR) signaling by modulating nuclear factor of activated T-cells (NFAT) and NF-κB activity, influencing antigen responsiveness. Rhythmic expression of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) under circadian control affects T cell adhesion to and transmigration across endothelium. Furthermore, circadian regulation of TCR, programmed cell death ligand 1 (PD-L1), TGF-β, and IL-10 expression influences tumor recognition and killing capacity in a time-dependent manner, offering insights for chronotherapy optimization in immunotherapy T cell migration and tumor infiltration Circadian clocks regulate the migratory capacity of T cells by modulating the expression of critical chemotactic factors within the TIME and lymphoid tissues, leading to time-dependent fluctuations in T cell trafficking. Specifically, BMAL1 controls the expression of endothelial adhesion molecules intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), affecting T cell adhesion to and transmigration across tumor vasculature, thereby creating a circadian “window of efficient migration” [241]. Moreover, the distribution of peripheral T cells between blood and tissues is under circadian control. At certain times, such as during nocturnal rest phases or early morning, the number of circulating T cells in peripheral blood increases, while during active phases, T cells preferentially migrate into tissues [295–297]. This rhythmic migration pattern implies that T cell infiltration into tumors varies over time, which may influence the strength of anti-tumor immune responses and critically affect the efficacy of immunotherapies, particularly adoptive T cell transfer (Fig. 7). T cell recognition and cytotoxicity against tumor cells The circadian clock influences multiple key steps of T cell recognition and killing of tumor cells. First, it regulates the expression and activity of T cell surface receptors, including the TCR and costimulatory molecules, thereby modulating T cell sensitivity to tumor antigens and activation efficiency. The strength of TCR signaling and the activation threshold of T cells fluctuate rhythmically, resulting in time-dependent variation in T cell recognition of tumor cells [258]. Second, the circadian clock governs the periodic expression of immunosuppressive factors within the TIME, such as PD-L1, TGF-β, and IL-10, which indirectly modulate T cell cytotoxic function [298]. During specific temporal windows when immunosuppression is attenuated, T cells exhibit enhanced effector functions, including perforin and granzyme release, leading to improved tumor cell killing. Conversely, during peaks of immunosuppressive factor expression, T cell cytotoxic efficiency is diminished (Fig. 7). Overall, the circadian clock coordinates the regulation of T cell recognition sensitivity, the immunosuppressive status of the TIME, and T cell metabolic function, collectively determining the time-dependent capacity of T cells to recognize and eradicate tumor cells. The TIME as a circadian-regulated immunometabolic battlefield Emerging chrono-immunological frameworks support the view that the TIME is not a static immunosuppressive compartment, but rather a “temporally organized battlefield” that is continuously shaped and dynamically remodeled by the circadian clock system. Within this framework, tumor metabolism, local clock machinery, vascular rhythmicity, immune cell trafficking, and immune effector functions form a highly coupled dynamic network that collectively determines the strength of antitumor immunity and therapeutic sensitivity across different temporal windows. Circadian clock systems within endothelial cells and the tumor stroma can rhythmically regulate the expression of adhesion molecules and chemokines, including ICAM-1, VCAM-1, CCL21, and CCR7, thereby establishing a process of “circadian immune gating” that controls immune cell entry into tumor tissues [241]. This mechanism contributes to the diurnal remodeling of the spatial immune architecture within the TIME and provides the spatial basis through which circadian clocks orchestrate periodic fluctuations in antitumor immune efficacy. During specific circadian phases, tumor vascular endothelium becomes more permissive to T cell adhesion and transendothelial migration, while DC migration to lymphatic tissues and antigen presentation efficiency are also enhanced. In contrast, during other phases, reduced endothelial chemotactic and adhesive capacity may restrict immune infiltration and tumor antigen presentation. Thus, immune cell trafficking within the TIME does not occur randomly but instead exhibits pronounced spatiotemporal migratory characteristics under circadian regulation. Once recruited into the TIME, immune cells undergo rhythmic reprogramming under the metabolic pressures generated during tumor progression, representing another key mechanism through which circadian clocks shape oscillations between immune surveillance and immunosuppressive states. Due to persistent aerobic glycolysis and abnormal oxygen metabolism in tumor cells, metabolic stress signals—including lactate, H⁺, ROS, and HIF-1α—accumulate periodically within the TIME [299]. Importantly, the production of these factors is not entirely constant but is influenced by residual circadian oscillations within tumor cells, fluctuations in nutrient availability, local perfusion dynamics, and systemic metabolic rhythms of the host, thereby exhibiting temporal variability. Recent studies have demonstrated that enhanced glycolytic activity and lactate accumulation can markedly dampen circadian oscillatory amplitude in both tumor cells and immune cells, particularly suppressing the expression of core clock components, ultimately leading to “clock flattening” within the local microenvironment [300, 301]. Meanwhile, lactate functions not merely as a metabolic byproduct but also as a signaling molecule capable of acidifying the TIME, suppressing mTOR signaling, stabilizing HIF-1α, and modulating NF-κB activity [302, 303]. Through these mechanisms, lactate further disrupts circadian coordination in immune cells, gradually shifting the TIME from a state of “rhythmic synchronization” toward one of “chronic chronodisruption.” Concurrently, inflammatory mediators released by TAMs, MDSCs, and tumor cells—including IL-1β, TNF-α, and IL-10—can further perturb local clock systems through JAK–STAT and NF-κB signaling pathways, thereby reshaping the temporal coordination capacity of immune cells [304, 305]. Ultimately, the TIME develops a dynamic “rhythmic immunosuppressive state,” characterized by temporal windows in which lactate, PD-L1, IL-10, and immunosuppressive myeloid populations reach peak abundance, whereas CD8⁺ T cell infiltration, TCR sensitivity, and cytotoxicity decline. In contrast, during other circadian windows, immunosuppressive pressures are relatively alleviated, allowing transient enhancement of antigen presentation, inflammatory activation, and cytotoxic immune function [306]. Accordingly, immune effector functions within the TIME are fundamentally time-dependent. The activation threshold of CD8⁺ T cells, release of perforin and granzymes, NK cell cytotoxicity, macrophage polarization states, and expression of immune checkpoint molecules such as PD-1 and PD-L1 are all regulated by circadian clock systems and exhibit phase-dependent functional variability. Recent evidence further suggests that T cell exhaustion is not a fixed terminal state but rather a dynamic process jointly shaped by metabolic stress and circadian regulation. During phases characterized by elevated lactate levels, hypoxia, and high PD-L1 expression, T cells are more prone to metabolic dysfunction and functional exhaustion. Conversely, during phases in which circadian rhythmicity is relatively preserved, T cells display greater mitochondrial adaptability and cytotoxic capacity [286]. In other words, tumor immune surveillance is not continuously stable but instead dynamically oscillates between “immune surveillance-dominant windows” and “immunosuppressive-dominant windows.” This conceptual framework also provides a mechanistic explanation for the temporal heterogeneity of immunotherapy responses. If immunotherapeutic interventions—such as chimeric antigen receptor T cell (CAR-T)/chimeric antigen receptor natural killer cell (CAR-NK) therapies or immune checkpoint blockade—are administered during phases when the TIME is in an immune-activated state, characterized by enhanced immune infiltration, active antigen presentation, lower lactate burden, and relatively moderate immune checkpoint expression, restoration of antitumor immunity may be more readily achieved. Conversely, treatment delivered during peaks of rhythmic immunosuppression may exhibit reduced efficacy due to intensified T cell exhaustion, metabolic restriction, and immune exclusion. Thus, the efficacy of immunotherapy may depend not only on the therapeutic agent itself but also on the circadian state of the TIME at the time of treatment. Increasingly, this phenomenon has been conceptualized as the “circadian gating of immunotherapy responsiveness,” whereby circadian rhythms temporally regulate sensitivity to immunotherapeutic interventions. Taken together, the TIME should be regarded as a dynamic immune ecosystem orchestrated by the circadian clock system. Within this ecosystem, tumor cells, immune cells, endothelial cells, and metabolic factors do not function independently but instead form a highly integrated spatiotemporal network through reciprocal circadian signaling. Tumor-derived metabolic stress remodels local clock architecture, local clocks subsequently regulate immune cell trafficking and infiltration rhythms, and the metabolic adaptability and effector functions of immune cells further reshape the rhythmic state of the TIME. Ultimately, periodic oscillations between immune surveillance and immunosuppressive states emerge, collectively determining tumor progression, immune escape, and the temporal responsiveness to immunotherapy. This “chrono-immunometabolic” model suggests that future cancer immunotherapy should not only target immune pathways themselves but also consider strategies aimed at restoring and exploiting circadian organization within the TIME in order to re-establish temporal synchronization of antitumor immunity. Circadian clock-based interventions for tumor immunity and immunotherapy response Immunotherapy has emerged as one of the most effective and transformative treatment modalities for malignant tumors by reactivating and sustaining the cancer–immune cycle, thereby restoring normal antitumor immune responses to control and eradicate tumors. In some cases, immunotherapy can even achieve complete remission [307]. The main immunotherapeutic approaches currently in clinical use include CAR-T therapy and ICB [308, 309]. CAR-T therapy involves the infusion of genetically engineered T cells that specifically recognize and kill tumor cells upon infiltration into the TIME [310]. Immune checkpoint blockade (ICB) therapy aims to restore endogenous T cell-mediated antitumor activity, for instance, by using antibodies against PD-1 to block inhibitory signals on T cells, thereby preventing tumor immune evasion and enhancing T cell cytotoxicity [311]. The efficacy of immunotherapy largely depends on the infiltration and functional status of CD8⁺ T cells, both of which are profoundly regulated by the circadian clock. Consequently, the intrinsic circadian machinery within tumor cells and immune cells, as well as exogenous circadian cues, represent critical determinants and actionable targets for modulating tumor responsiveness to immunotherapy. Recent studies have underscored the importance of temporal windows in immunotherapy efficacy. Tumor cell-intrinsic BMAL1 expression regulates T cell activity within the TIME, thereby influencing clinical responses to immune checkpoint inhibitors [312]. CD8⁺ T cell infiltration in melanoma exhibits significant circadian rhythmicity that dictates the response to anti-PD-1 therapy [11]. Similarly, rhythmic expression of BMAL1 and CLOCK in lung cancer cells correlates with oscillations in PD-1/PD-L1 expression levels, which profoundly impact tumor growth rates in immunotherapy-treated animal models. Moreover, the timing of immune checkpoint inhibitor administration significantly affects clinical outcomes in patients [313]. Collectively, these findings establish the circadian clock as a pivotal biomarker for predicting tumor immunotherapy efficacy. Furthermore, it represents a crucial regulator of tumor cells and the TIME, offering novel avenues to reshape immune surveillance and enhance therapeutic responsiveness. Exploiting the circadian rhythm mechanism to modulate the immune system offers a novel strategy for enhancing tumor immunotherapy (Table 1). Table 1Intervention strategies targeting the circadian clock [73, 314–317]Intervention TypeMechanism/MethodEffectsResearch/Application StatusSmall-molecule circadian modulatorsUse of REV-ERB agonists (e.g., SR9009) to regulate circadian proteinsModulate immune cell function, enhance immune clearanceStudied in animal models; clinical exploration ongoingChronotherapy of immune checkpoint inhibitors (ICIs)Optimize timing of ICI (e.g., anti-PD-1/PD-L1) administrationLeverage immune cell circadian rhythms to improve efficacyTime-dependent dosing explored in clinical trialsDietary/behavioral modulation (TRF)Synchronize biological clocks, promote immune cell activityImprove immune metabolism, strengthen antitumor responsesEarly-stage animal and small-scale clinical studiesLight therapyRegulate systemic circadian rhythm, indirectly modulate immune statusPromote circadian synchrony, improve immune functionAdjunct therapy Intervention strategies targeting the circadian clock [73, 314–317] Drug intervention targeting the circadian clock One approach involves directly targeting core circadian regulators such as BMAL1, CLOCK, PER, CRY, and REV-ERB using small-molecule compounds (e.g., the REV-ERB agonist SR9009) to reset the rhythmic state of immune or tumor cells (Table 2). This “clock modulation” can reduce the expression of immunosuppressive factors, augment immune cell infiltration and cytotoxicity within the TIME, thereby enhancing tumor immune clearance. Moreover, disruption of intrinsic circadian rhythms in tumors is often associated with immune evasion, suggesting that restoring circadian synchrony may also reverse immune suppression. Table 2Pharmacological agents targeting circadian regulators [314, 318–336]CompoundMolecular TargetClock ComponentMechanism of ActionDevelopment StageGSK4112REV-ERBαREV-ERBSynthetic agonistResearch tool (in vitro)SR9009REV-ERBα/βREV-ERBAgonist-like ligandPreclinicalSR9011REV-ERBα/βREV-ERBAgonistPreclinicalSR8278REV-ERBαREV-ERBAntagonistResearch toolKL001CRY1/CRY2CryptochromeCRY stabilizerResearch toolKL044CRY1/CRY2CryptochromeCRY stabilizerResearch toolKL048CRY1/CRY2CryptochromeCRY stabilizerResearch toolKL062CRY1/CRY2CryptochromeCRY stabilizerEarly preclinicalPF-670,462CK1δ/εPER pathwayKinase inhibitor; stabilizes PER proteinsPreclinical / Early clinicalPF-4,800,567CK1εPER pathwayKinase inhibitorPreclinicalCKI-7CK1δ/εPER pathwayKinase inhibitorResearch toolIC261CK1δ/εPER pathwayKinase inhibitorPreclinicalD4476CK1δ/εPER pathwayKinase inhibitorPreclinicalBTX-A51CK1α/CK1δPER pathwayKinase inhibitorEarly clinicalLYC-53,772RORγRORAgonistPreclinicalLYC-54,143RORγRORAgonistPreclinicalLYC-55,716 (Cintirorgon)RORγRORAgonistPhase I/II clinicalSR1078RORα/γRORAgonistPreclinicalSR3335RORαRORInverse agonistResearch tool / PreclinicalGSK805RORαRORInverse agonistPreclinicalMLN4924 (Pevonedistat)NEDD8-activating enzymeRORα (indirect)Neddylation inhibitorPhase III clinicalNobiletinRORs / Clock modulatorROR / Clockenhances circadian amplitudePreclinical / Early clinical Pharmacological agents targeting circadian regulators [314, 318–336] The expression of immune checkpoints is regulated by core circadian clock components such as RORα and PER2 [132, 145]. Understanding the mechanisms and regulatory nodes by which the circadian clock modulates immune checkpoint expression within the TIME is critical for developing circadian-targeted adjuncts to cancer immunotherapy. Although numerous preclinical and clinical studies have demonstrated the promising potential of this approach, drug development remains in the early stages. Representative compounds include synthetic RORγ agonists LYC-53,772 and LYC-54,143, which promote Th17 cell differentiation and block Treg-driven immunosuppressive tumor microenvironments, significantly elevating antitumor cytokines such as IL-17 A, IL-17 F, IL-22, and GM-CSF [337]. Additionally, these agonists can induce T cell tolerance to PD-L1 and enhance the antitumor activity of CAR-T cells [329]. Through multiple synergistic mechanisms, these agents upregulate endogenous antitumor immunity and improve immunotherapy outcomes. Behavioral interventions targeting the circadian clock Chronotherapy in immunotherapy Another promising strategy focuses on optimizing the timing of immunotherapy administration—particularly ICIs—based on the principles of chronotherapy. By delivering treatments during the immune system’s peak sensitivity and activity windows, therapeutic efficacy can be enhanced while minimizing adverse effects. For example, administering PD-1/PD-L1 blockade at the peak of T cell activity may significantly boost antitumor efficacy. This concept is supported by animal experiments and preliminary clinical evidence, and the application of individualized circadian monitoring technologies is expected to further improve feasibility. On one hand, epithelial circadian clocks regulate cytokine secretion to drive rhythmic immune landscapes, which in turn control the oscillations in MDSC abundance and the secondary rhythmic activation/inhibition states of cytotoxic CD8 + T cells [286]. On the other hand, PD-1 expression on tumor-associated macrophages shows pronounced circadian oscillations [276]. These factors collectively contribute to the time-dependent efficacy of ICIs. Clinical data confirm significant temporal dependence of ICI efficacy in melanoma, non-small cell lung cancer, and esophageal cancer [338–341]. Similarly, in melanoma mouse models, the antitumor effects of CAR-T therapy exhibit strong time-of-day dependence, highlighting the crucial role of circadian phase in regulating host antitumor immunity. Growing evidence suggests that the significance of chronotherapy in cancer immunotherapy extends beyond simply improving therapeutic efficacy; more fundamentally, it may determine whether immune activation ultimately leads to sustained antitumor immunity or instead drives T-cell dysfunction and exhaustion [342]. Although ICIs, such as PD-1/PD-L1 blockade, can restore cytotoxic T-cell activity by relieving inhibitory signaling, recent studies increasingly indicate that excessive or improperly timed immune activation may also accelerate the transition of T cells toward terminal exhaustion [342, 343]. This issue is particularly important within the TIME, where chronic inflammation and persistent metabolic stress often place tumor-infiltrating T cells at the threshold of functional instability, rendering them vulnerable to additional exogenous activation that may exceed their metabolic and functional tolerance limits. Under physiological conditions, antitumor immunity is not constitutively activated but instead operates as a dynamically organized process tightly coordinated by the circadian clock system. Immune-cell trafficking, antigen presentation, cytokine secretion, endothelial adhesion signaling, and cellular metabolic adaptability all exhibit pronounced circadian oscillations. Consequently, CD8⁺ T cells undergo cyclical transitions between migratory, activated, effector, and recovery states across different circadian phases [258]. Importantly, these immune rhythms are normally synchronized with metabolic rhythms, including nutrient availability, mitochondrial activity, and tissue permeability, thereby ensuring that immune activation remains metabolically sustainable [344]. In this context, endogenous circadian organization may function not only to optimize antitumor immune efficiency but also to prevent chronic functional deterioration caused by persistent high-intensity immune activation. However, ICI therapy essentially introduces an “artificial sustained immune activation” signal into this intrinsically oscillatory system. When immune checkpoint blockade is administered during circadian phases characterized by active antigen presentation, enhanced immune infiltration, improved mitochondrial adaptability, and relatively favorable metabolic support, reactivated T cells are more likely to maintain durable cytotoxic functionality and generate effective antitumor immunity. In contrast, if ICI administration occurs during biologically unfavorable circadian phases—such as periods associated with elevated lactate accumulation, intensified hypoxia, reduced endothelial adhesive capacity, or increased immunosuppressive cytokine activity—T cells may become forcibly reactivated in the absence of sufficient metabolic support and tissue coordination. Under such conditions, reactivated T cells may fail to establish sustained immune responses and instead become more susceptible to excessive energetic stress, mitochondrial dysfunction, ROS accumulation, and chronic inflammatory stimulation, ultimately accelerating their progression toward dysfunctional states [345]. Recent advances in the study of T-cell exhaustion further support this perspective. Increasing evidence suggests that T-cell exhaustion is not merely a consequence of persistent antigen exposure, but rather a progressive differentiation program closely linked to metabolic insufficiency, epigenetic fixation, and chronic stress signaling [346]. Within the metabolically hostile TIME, prolonged PD-1 blockade may disrupt the endogenous balance of immune rhythmicity, causing T-cell activation to become temporally uncoupled from physiological phases of metabolic recovery, tissue repair, and functional buffering. Such “non-rhythm-synchronized activation” may maintain T cells in a prolonged hyperactivated state while depriving them of opportunities for metabolic restoration and functional resetting, ultimately leading to the gradual loss of proliferative capacity, cytokine production, and cytotoxic function [345]. From the perspective of chrono-immunology, ICI administration during inappropriate circadian phases may therefore not only reduce therapeutic efficacy but also actively promote treatment-associated immune dysfunction and T-cell exhaustion. Accordingly, the efficacy of immunotherapy depends not only on the magnitude of immune activation itself, but also on whether such activation remains temporally synchronized with endogenous immune and metabolic rhythms. The central objective of circadian-based immunotherapeutic strategies may therefore extend beyond identifying the “most effective” administration time to identifying optimal temporal windows capable of simultaneously sustaining immune effector function while preserving immune homeostasis. In other words, chronotherapy may enhance antitumor immunity not only by amplifying immune responses, but also by reducing the risk of therapy-induced dysfunction and exhaustion through preventing excessive T-cell activation during biologically unfavorable circadian phases. These considerations suggest that future immunotherapeutic strategies may need to integrate circadian phase, TIME metabolic characteristics, and dynamic immune states in order to achieve truly temporally precise immunotherapy. Behavioral circadian interventions in tumor immunotherapy Behavioral interventions—such as TRF, regular sleep patterns, and light therapy—are emerging as adjunct approaches to reshape circadian rhythms, with the potential to improve immune function and synergize with pharmacological treatments to enhance overall antitumor efficacy. The future success of these strategies will rely on integrative multi-omics data, advances in individualized circadian rhythm assessment technologies, and continued development of circadian-targeted drugs, enabling more precise and effective immunotherapeutic regimens. In tumor immunotherapy, behavioral circadian interventions represent novel non-pharmacological approaches to optimize immune function and enhance treatment responses by resetting the biological clock. Behavioral interventions such as maintaining regular routines, ensuring sufficient sleep, and avoiding circadian disruption are fundamental for restoring circadian homeostasis. Both experimental and clinical studies indicate that chronic circadian disruption (e.g., shift work, chronic sleep deprivation) impairs immune tumor surveillance, increases cancer risk, and diminishes immunotherapy responsiveness. Stable sleep-wake cycles facilitate rhythmic immune cell function and improve the therapeutic window for immune checkpoint inhibitors [347]. Behavioral factors including light exposure, feeding schedules, and physical activity serve as critical external zeitgebers that synchronize endogenous clocks. Moderate daytime light enhances circadian amplitude and daytime immune activity [348, 349], while minimizing nocturnal exposure to bright light preserves melatonin secretion and supports immune cell recovery [350–353]. TRF shows promising immunomodulatory effects by synchronizing peripheral clocks, improving immune metabolism, and modulating gut microbiota, indirectly potentiating antitumor immunity. Regular exercise stabilizes circadian rhythms, optimizes metabolic health, and increases circulating immune cells [73, 354–356]. Our previous studies demonstrated that feeding rhythm interventions remodel the TIME by shifting TAMs from pro-tumorigenic M2 to antitumor M1 phenotypes via metabolic and inflammatory pathway modulation, thereby enhancing T cell activity and tumor recognition [357]. Clinical studies have shown that strengthening feeding rhythms induces rhythmic gene expression in tumor cells and suppresses tumor progression, although the precise molecular mechanisms remain incompletely understood. We hypothesize that this effect is closely linked to the regulation of the cellular circadian clock by feeding rhythms, potentially via activation of the PI3K/AKT/mechanistic target of rapamycin (mTOR) (PAM) signaling axis. The PAM pathway is one of the most frequently dysregulated signaling cascades in human cancers and is closely associated with resistance to immunotherapy. Aberrations such as PI3K hyperactivation, loss-of-function mutations in PTEN, and constitutive activation of AKT are major drivers of tumor progression and therapeutic resistance [231, 358]. Feeding rhythms stimulate IR and IGFR activation in tumor cells, which in turn triggers PI3K-mediated accumulation of PIP3 and subsequent activation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) [359]. Simultaneously, PI3K facilitates mammalian target of rapamycin complex 2 (mTORC2) activation [360]. PDK1 phosphorylates AKT at Thr308, while mTORC2 phosphorylates AKT at Ser473; dual-site phosphorylation fully activates AKT. Activated AKT regulates glucose metabolism, protein synthesis, cell proliferation, survival, and apoptosis through a range of downstream targets [361]. Notably, AKT phosphorylation facilitates Glut translocation to the plasma membrane, promoting tumor cell glucose uptake. Phosphorylated AKT also inactivates GSK3, forkhead box O (FOXO), and tuberous sclerosis complex 1 (TSC1)/tuberous sclerosis complex 2 (TSC2), thereby activating Wnt signaling, inhibiting apoptosis, and stimulating mTORC1 activity, respectively [361]. Additionally, AKT-mediated phosphorylation of B-cell lymphoma 2 (BCL-2) promotes cell survival, while inhibition of P27 and Bad suppresses cell cycle arrest and apoptosis. Importantly, feeding-induced insulin oscillations modulate the PI3K–AKT–mTOR pathway in tumor cells, profoundly influencing PD-L1 protein levels. This regulation occurs primarily at the post-translational level: insulin signaling stabilizes PD-L1 protein by preventing ubiquitin-mediated degradation rather than altering its transcription. Conversely, under glucose-deprived conditions, activation of AMPK—a central cellular energy sensor—facilitates PD-L1 degradation. In murine tumor models, pharmacologic modulation of tumor metabolic states, such as with AMPK agonists, markedly enhances the therapeutic efficacy of PD-1/PD-L1 immune checkpoint blockade [362]. Together, these findings suggest that feeding behavior rhythmically shapes tumor metabolic status and immune evasion through PD-L1 stabilization, providing a strong rationale for integrating metabolic rhythm interventions with immunotherapy. In our previous study, we demonstrated that feeding rhythm interventions can reprogram tumor-associated macrophage (TAM) phenotypes and enhance the efficacy of anti–PD-L1 immunotherapy in hepatocellular carcinoma (HCC). Specifically, short-term starvation (STS) promotes TAM polarization from an immunosuppressive M2 phenotype to a pro-inflammatory M1 state, thereby increasing phagocytic activity and stimulating CD8⁺ T cell–mediated anti-tumor immunity. Across multiple murine HCC models, the combination of STS with anti–PD-L1 therapy markedly suppressed tumor progression [357]. These findings provide a strong rationale for incorporating circadian rhythm interventions, such as fasting or feeding-time modulation, into combination immunotherapy strategies to remodel the TIME and improve clinical outcomes in cancer treatment. In summary, behavioral circadian interventions offer low-toxicity, sustainable adjunctive approaches for cancer immunotherapy (Table 3). Combining individualized biological clock assessment, wearable device monitoring, and precise timing interventions holds promise for developing personalized “rhythm-optimized” immunotherapeutic strategies that improve efficacy and reduce adverse effects. Table 3Clinical trials targeting circadian regulators [363–368]Trial IDStudy Title/ObjectiveTarget/FocusPhaseIndication/Tumor TypeFindingsNCT02595320Chronomodulated capecitabine immunotherapy—Phase IILocally advanced primary rectal cancerCapecitabine chronotherapy combined with adjuvant radiotherapy is feasible and tolerableNot registered on ClinicalTrialsTimed infusion of 5-fluorouracil and 5-fluorodeoxyuridine—Phase IIColorectal cancer liver metastasesSupports chronotherapy in arterial and venous fluoropyrimidine chemotherapy for colorectal liver metastasesNot registered on ClinicalTrials4’-O-tetrahydropyranyl doxorubicin and cisplatin—Phase IIAdvanced ovarian cancerMorning doxorubicin and afternoon cisplatin reduce toxicityNot registered on ClinicalTrialsCetuximab with chronomodulated chemotherapy—Phase IIMetastatic colorectal cancerCetuximab combined with chronotherapy provides safe and effective metastatic controlNCT02929862(in progress, not yet published)RORγ agonist: safety, objective response rate, duration of response, biomarkersRORγ agonistsPhase 2aRecurrent/refractory metastatic cancersOral RORγ agonist LYC-55,716 is well-tolerated with target-mediated pharmacodynamics and antitumor activityNCT00911066Safety and preliminary efficacy of NEDD8-activating enzyme targeting RORα stabilizersRORα stabilizersPhase IAcute myeloid leukemia (AML)RORα stabilizers show acceptable safety, tolerability, and some clinical activity in AML and MDS Clinical trials targeting circadian regulators [363–368] Conclusion and perspectives The circadian clock is closely related to key biological processes such as immunity, cell cycle control, DNA damage response, DNA repair, and metabolism. Once these processes are disrupted, they can lead to cancer. Over the past decade, growing recognition of the circadian system as a central regulator of anti-tumor immunity and the occurrence, progression, and response to treatment of tumors has reshaped our understanding of cancer biology and immunology. This review has highlighted how circadian clocks, traditionally viewed as molecular oscillators coordinating sleep, metabolism, and endocrine functions, serve as pivotal modulators of tumor immunity. By integrating intrinsic transcription–translation feedback loops with systemic neuroendocrine rhythms and behavioral cues such as feeding and sleep–wake cycles, the circadian machinery orchestrates immune surveillance across both physiological and pathological states. Mounting experimental and clinical evidence demonstrates that circadian misalignment accelerates tumorigenesis, reprograms metabolic pathways, and undermines host defense by impairing the cellular metabolic homeostasis, genetic homeostasis and the functionality of key immune subsets, such as dendritic cells, macrophages, and cytotoxic T lymphocytes [96, 369–371]. Conversely, restoration or reinforcement of circadian integrity has been shown to enhance antigen presentation, re-invigorate exhausted T cells, and remodel the TIME toward a more immunostimulatory state [181, 372–374]. Collectively, these findings highlight circadian regulation as an important component influencing tumor progression and therapeutic responsiveness, supporting the integration of chronobiological perspectives into both experimental and clinical oncology. At present, several agents targeting circadian clock–related molecules have entered early-stage clinical investigation. For example, RORγ-related modulators such as LYC-55,716 and LYC-54,143 have advanced into preliminary clinical trials. Meanwhile, a number of studies investigating the optimization of administration timing for immunotherapy, targeted therapy, and chemotherapy have suggested that specific dosing schedules may be associated with improved therapeutic responses or reduced toxicity. However, most of these studies remain exploratory in nature, with limited sample sizes, substantial patient heterogeneity, and a lack of standardized circadian assessment criteria, all of which restrict the broader generalizability of their findings. Overall, current evidence suggests that circadian-based interventions may hold clinical potential; however, their precise mechanisms, optimal intervention strategies, and applicability across different patient populations still require further validation through large-scale and standardized studies [331, 375–379]. Despite important advances in recent years in the fields of circadian biology and tumor immunity, and the gradual introduction of chronotherapy, temporally optimized immunotherapy, and behavioral rhythm interventions into clinical exploration, substantial barriers still hinder their broad clinical translation. Most current studies remain focused on proof-of-concept observations and mechanistic investigations in experimental models, whereas standardized and clinically applicable approaches for accurately identifying, dynamically monitoring, and therapeutically modulating circadian states within the TIME in real-world patients are still lacking. Therefore, rather than viewing circadian rhythms simply as novel therapeutic targets, it may be more appropriate to consider the circadian system as a highly dynamic, individualized, and multi-level biological organizational framework whose inherent complexity itself represents a major translational challenge. One of the most critical obstacles is the absence of biomarkers capable of non-invasively and dynamically reflecting the local circadian state of tumors in real time. Although melatonin rhythms, cortisol oscillations, body temperature fluctuations, activity monitoring, and peripheral clock gene expression have been used to evaluate systemic circadian status, accumulating evidence indicates that peripheral rhythms do not necessarily accurately reflect the true clock phase within the TIME [380]. Particularly in advanced tumors, persistent hypoxia, lactate accumulation, chronic inflammation, and metabolic reprogramming may generate a state of partial tumor–host circadian uncoupling. Moreover, distinct tumor regions may exhibit heterogeneous local rhythmic oscillations, while immune cells, tumor cells, and endothelial cells within the TIME may exist in desynchronized clock states [301]. Consequently, reliance solely on peripheral temporal markers may be insufficient to accurately identify the true intratumoral “therapeutic window”. Recent advances in single-cell transcriptomics, spatial transcriptomics, circulating metabolomics, and wearable physiological monitoring technologies have provided new opportunities for circadian-state assessment; however, these approaches remain limited by high cost, insufficient temporal resolution, and the absence of unified analytical frameworks. Thus, establishing multidimensional dynamic biomarker systems capable of integrating host behavioral rhythms, systemic physiological rhythms, and local TIME circadian states remains a major challenge for the clinical translation of chrono-immunotherapy. In addition, the marked heterogeneity of individual circadian rhythms further complicates the standardization of chronotherapeutic strategies. Traditional chronotherapy generally assumes relatively stable and predictable circadian structures among patients. However, modern lifestyles—including shift work, sleep deprivation, transmeridian travel, irregular feeding behaviors, and prolonged exposure to electronic devices—have substantially altered population-wide biological rhythms. In particular, chronic circadian misalignment may already constitute a persistent physiological background in long-term shift workers and other special occupational groups. Under such conditions, even when treatments are administered at the same “clock time”, the actual biological time of individual patients may differ substantially. Furthermore, chronotype studies have demonstrated significant interindividual differences associated with age, sex, metabolic status, gut microbiota composition, and tumor burden [381–383]. These findings suggest that future chronotherapy may need to evolve from “fixed-time treatment” toward “biological time-guided therapy” tailored to individual circadian states. Meanwhile, growing evidence suggests that rhythmic regulation within the TIME fundamentally represents a complex dynamic system spanning multiple cell types, tissue layers, and metabolic networks. Tumor cells, immune cells, fibroblasts, vascular endothelial cells, and the gut microbiota all participate in highly coupled rhythmic interactions [382]. Consequently, modulation of a single clock molecule alone may be insufficient to comprehensively restore the rhythmic organization of the TIME. Increasingly, studies have proposed the concept of “circadian network remodeling”, suggesting that circadian dysregulation in tumors may arise not from isolated clock gene abnormalities, but rather from the collapse of synchronization across local rhythmic networks [384]. This implies that future interventions may need to shift from single-target clock modulation toward more systematic strategies aimed at restoring circadian network organization. Another important yet incompletely resolved issue is the potential “double-edged sword” effect of circadian interventions. Although restoration of circadian integrity is generally considered beneficial for enhancing antitumor immunity, different tumor types may exhibit distinct dependencies on clock systems. In some tumors, certain clock genes may even be exploited by tumor cells to support metabolic adaptation, DNA repair, or therapeutic resistance [373, 385]. Furthermore, in the context of ICI therapy, exogenous immune activation that is temporally misaligned with endogenous immune recovery rhythms may force T cells into prolonged states of elevated metabolic stress, ultimately accelerating functional exhaustion [286]. Therefore, future chrono-immunotherapy strategies may need to focus not only on enhancing immune activation but also on preserving rhythmic immune homeostasis. Nevertheless, these challenges also provide clear directions for future research. Advances in artificial intelligence–assisted circadian modeling, multi-omics integration, single-cell chronobiology, spatial transcriptomics, and digital behavioral monitoring are gradually enabling the development of personalized circadian medicine [386–388]. In the future, integrating sleep behaviors, metabolic states, hormonal rhythms, gut microbiota dynamics, and local immune rhythmicity within the TIME may facilitate the establishment of more precise “dynamic temporal atlases”, thereby enabling real-time prediction and precision modulation of tumor immune states. Overall, the role of the circadian system in tumor immunity has gradually evolved from a basic biological phenomenon into an important conceptual framework for understanding the dynamic organizational principles of the TIME. However, its clinical translation still faces multiple challenges, including difficulties in circadian-state monitoring, substantial interindividual heterogeneity, the complexity of local clock organization within the TIME, and insufficient precision of current intervention strategies. Ultimately, the key challenge is no longer simply to demonstrate that circadian rhythms influence tumor immunity, but rather to determine how circadian structures within the TIME can be accurately identified, dynamically modulated, and stably restored in the context of highly heterogeneous and complex human physiological environments. This may ultimately determine whether chrono-immunotherapy can progress from an attractive theoretical concept into a broadly applicable clinical strategy. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements Not applicable. Abbreviations Acute myeloid leukemia AMP-activated protein kinase Arginase 1 Aryl hydrocarbon receptor nuclear translocator Ataxia-telangiectasia mutated proteins ATM and Rad3 related kinase B-cell lymphoma 2 Brain and Muscle ARNT-Like 1 Cancer-associated fibroblast Chimeric antigen receptor natural killer cell Chimeric antigen receptor T cell Cyclin A1 C-C motif chemokine ligand 2 C-C motif chemokine ligand 21 C-C chemokine receptor type 7 Cyclin-dependent kinase 1 Checkpoint kinase 1 Checkpoint kinase 2 Circadian locomotor output cycles kaput cAMP-response elements cAMP response element-binding protein Cryptochrome1 Cryptochrome2 Cancer stem cells Cytotoxic T-lymphocyte-associated protein 4 C-X-C chemokine receptor type 3 Dendritic cell DNA damage response Direct repeat 2 Double-strand breaks Extracellular matrix Epithelial-mesenchymal transition Extracellular regulated protein kinase Free fatty acid receptor 2 Free fatty acid receptor 3 Forkhead box O Gut-associated lymphoid tissue Glioblastoma Glucagon receptor G protein-coupled receptor Glutathione peroxidase 4 Glycogen synthase kinase-3 beta Glucose-6-phosphate dehydrogenase Hydroxycarboxylic acid receptor 2 Hepatocellular carcinoma Histone deacetylase 3 Hypoxia-inducible factor Hypoxia-inducible factor-1α Hypothalamic-pituitary-adrenal Homologous recombination Heat shock factor 1 H4 acetylation International Agency for Research on Cancer Intercellular adhesion molecule 1 Immune checkpoint blockade Insulin-like growth factor 1 Insulin-like growth factor 1 receptor Checkpoint inhibitors Innate lymphoid cells Interleukin-1 Interleukin-10 Interleukin-1β Insulin receptor Janus kinase Lactate dehydrogenase A Legumain Lymphatic vessel endothelial hyaluronan receptor 1 Myeloid-derived suppressor cells Matrix metalloproteinase 9 Mitochondrial reactive oxygen species Mechanistic target of rapamycin Mammalian target of rapamycin complex 1 Mammalian target of rapamycin complex 2 MicroRNAs Myofibroblastic CAFs Nucleotide excision repair Nuclear factor of activated T-cells Natural killer cells Nuclear Receptor Subfamily 1 Group D Member 1 Nuclear factor erythroid 2–related factor 2 Nuclear Receptor Subfamily 1 Group D Member 2 Olfactomedin-like protein 3 Oligodendrocyte transcription factor 2 Oxyntomodulin Plasminogen activator inhibitor-1 PI3K/AKT/mTOR PER–ARNT–SIM Phosphoenolpyruvate carboxykinase 1 3-phosphoinositide-dependent protein kinase-1 Programmed death-ligand 1 Programmed cell death protein 1 Period circadian regulator 1 Period Circadian Regulator 2 Period circadian regulator 3 Prostaglandin E2 Phosphoinositide 3-kinase Phosphatidylinositol (3,4,5)-trisphosphate Protein kinase A Pyruvate kinase muscle isozyme M2 Periostin Peroxisome proliferator-activated receptor alpha Nuclear Receptor Subfamily 1 Group D Member 1 Nuclear Receptor Subfamily 1 Group D Member 2 RNA polymerase II Retinoic acid–related orphan receptor Retinoic acid–related orphan receptor alpha Retinoic acid–related orphan receptor beta Retinoic acid–related orphan receptor gamma Reactive oxygen species SREBP cleavage-activating protein Short-chain fatty acids Suprachiasmatic nucleus Succinate dehydrogenase Solute carrier family 7 member 11 Sma and Mad related protein 2 Sma and Mad related protein 3 Nail family transcriptional repressor 1 SRY-box transcription factor 2 SREBP regulating gene protein Sterol regulatory element-binding protein 2 Slingshot homolog 1 single-stranded DNA Signal transducer and activator of transcription 3 Short-term starvation Tumor-associated macrophages TANK-binding kinase 1 Tricarboxylic acid T cell receptor Transforming growth factor-β Tumor-infiltrating lymphocytes Triosephosphate isomerase Tumor immune microenvironment Tumor Necrosis Factor alpha Time-restricted feeding Regulatory T cells Tuberous sclerosis complex 1 Tuberous sclerosis complex 2 Transcription–translation feedback loop Tissue plasminogen activator Urokinase plasminogen activator Vascular cell adhesion molecule 1 Vascular endothelial growth factor Xeroderma pigmentosum group A Author contributions ZWG and CK: Conceived and designed the study; supervised the overall project; contributed to manuscript revision. WH, GB, LDF and: Conducted literature review; drafted the initial manuscript; created figures and tables. LHF: Provided conceptual insights; helped with structuring the review and editing the final version. All authors read and approved the final manuscript. Funding This work was supported by the National Natural Science Foundation of China (No. 82373054 to Wanguang Zhang), the Fundamental Research Funds for the Central Universities, HUST (No. YCIJ20252402) and Special Fund for Science and Technology Innovation of Hubei Province (No. SCZ202461). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Hao Wang, Bin Guo, Danfeng Li and Yuxi Liu are co-first authors. Contributor Information Kun Cheng, Email: ck1597055624@163.com. Wanguang Zhang, Email: wgzhang@tjh.tjmu.edu.cn. Huifang Liang, Email: lianghuifang1997@126.com, Email: hfliang@tjh.tjmu.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.